<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Nivolumab: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Nivolumab: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Nivolumab: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="98764" href="/d/html/98764.html" rel="external">see "Nivolumab: Drug information"</a> and <a class="drug drug_patient" data-topicid="99274" href="/d/html/99274.html" rel="external">see "Nivolumab: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F26819875"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Opdivo</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52871869"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Opdivo</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F50189836"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antineoplastic Agent, Anti-PD-1 Monoclonal Antibody</span>;</li>
<li>
<span class="list-set-name">Antineoplastic Agent, Immune Checkpoint Inhibitor</span>;</li>
<li>
<span class="list-set-name">Antineoplastic Agent, Monoclonal Antibody</span></li></ul></div>
<div class="block dop drugH1Div" id="F50509392"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Dosing units vary; may be based on weight (<b>mg/kg</b>) or a fixed dose (mg); use caution. Nivolumab and nivolumab/relatlimab are different products and are <b>not</b> interchangeable; verify product selection to ensure appropriate product.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="769d5e2a-1b38-4db1-88c9-3311a2a0e438">Colorectal cancer, metastatic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Colorectal cancer, metastatic (microsatellite instability-high [MSI-H] or mismatch repair deficient [dMMR]):</b>
<b>Note:</b> FDA approval is through an accelerated process; continued approval is dependent upon verification of clinical benefit in further trials.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Single-agent nivolumab therapy:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥12 years and Adolescents:</p>
<p style="text-indent:-2em;margin-left:8em;">&lt;40 kg: IV: 3 <b>mg/kg</b> every 2 weeks until disease progression or unacceptable toxicity.</p>
<p style="text-indent:-2em;margin-left:8em;">≥40 kg: IV: 240 mg every 2 weeks or 480 mg every 4 weeks until disease progression or unacceptable toxicity.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Combination therapy with ipilimumab: </i></p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥12 years and Adolescents:</p>
<p style="text-indent:-2em;margin-left:8em;">&lt;40 kg: IV: 3 <b>mg/kg</b> every 3 weeks (in combination with ipilimumab) for 4 doses (or less if unacceptable toxicity occurs), followed by 3 <b>mg/kg</b> once every 2 weeks (nivolumab monotherapy) until disease progression or unacceptable toxicity. <b>Note:</b> If nivolumab therapy is withheld, ipilimumab should also be withheld.</p>
<p style="text-indent:-2em;margin-left:8em;">≥40 kg: IV: 3 <b>mg/kg</b> every 3 weeks (in combination with ipilimumab) for 4 doses (or less if unacceptable toxicity occurs), followed by 240 mg once every 2 weeks or 480 mg once every 4 weeks (nivolumab monotherapy) until disease progression or unacceptable toxicity. <b>Note:</b> If nivolumab therapy is withheld, ipilimumab should also be withheld.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9b174bbe-b5b5-4ffc-a5e7-841e14948c85">Melanoma; unresectable or metastatic or adjuvant treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Melanoma; unresectable or metastatic or adjuvant treatment: Note: </b>For treatment of unresectable or metastatic melanoma, may use as a single agent or in combination with ipilimumab; continue until disease progression or unacceptable toxicity. When used as adjuvant treatment of melanoma, use in patients with involvement of lymph nodes or metastatic disease who have undergone complete resection; continue until disease progression or unacceptable toxicity for up to 1 year duration.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Single-agent nivolumab therapy:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥12 years and Adolescents:</p>
<p style="text-indent:-2em;margin-left:8em;">&lt;40 kg: IV: 3 <b>mg/kg</b> every 2 weeks or 6 <b>mg/kg</b> every 4 weeks.</p>
<p style="text-indent:-2em;margin-left:8em;">≥40 kg: IV: 240 mg every 2 weeks or 480 mg every 4 weeks.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Combination therapy with ipilimumab: </i></p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥12 years and Adolescents:</p>
<p style="text-indent:-2em;margin-left:8em;">&lt;40 kg: IV: 1 <b>mg/kg</b> every 3 weeks (in combination with ipilimumab) for 4 doses (or less if unacceptable toxicity occurs), followed by 3 <b>mg/kg</b> once every 2 weeks or 6 <b>mg/kg</b> once every 4 weeks (nivolumab monotherapy) until disease progression or unacceptable toxicity. <b>Note:</b> If nivolumab therapy is withheld, ipilimumab should also be withheld.</p>
<p style="text-indent:-2em;margin-left:8em;">≥40 kg: IV: 1 <b>mg/kg</b> every 3 weeks (in combination with ipilimumab) for 4 doses (or less if unacceptable toxicity occurs), followed by 240 mg once every 2 weeks or 480 mg once every 4 weeks (nivolumab monotherapy) until disease progression or unacceptable toxicity. <b>Note:</b> If nivolumab therapy is withheld, ipilimumab should also be withheld.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7177d86f-32ee-49d7-9ed7-ee88e7f0a1c0">Solid tumors, relapsed/refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Solid tumors, relapsed/refractory: </b>Very limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Combination therapy with ipilimumab: </i></p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥4 years and Adolescents: IV: 3 <b>mg/kg</b> every 3 weeks (in combination with ipilimumab) for 4 doses (or less if unacceptable toxicity occurs), followed by 3 <b>mg/kg</b> every 2 weeks until disease progression or unacceptable toxicity (Davis 2022).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosing adjustment for toxicity:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥12 years and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> No dosage reductions of nivolumab are recommended. When nivolumab is given in combination with ipilimumab, withhold or permanently discontinue both nivolumab and ipilimumab for adverse reactions meeting dosage modification recommendations. Other concomitant combination therapy medications may also require treatment interruption, dosage reduction, and/or discontinuation.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Immune-mediated adverse reactions (general information):</b> Withhold nivolumab for severe (grade 3) immune-mediated adverse reactions. Permanently discontinue nivolumab for life-threatening (grade 4) immune-mediated adverse reactions, recurrent severe (grade 3) immune-mediated reactions that require systemic immunosuppressive treatment, or inability to reduce corticosteroid dose to prednisone ≤10 mg/day (or equivalent) within 12 weeks of initiating corticosteroids. If nivolumab treatment interruption or discontinuation is required, administer systemic corticosteroids (1 to 2 mg/kg/day prednisone [or equivalent]) until improvement to ≤ grade 1; upon improvement to ≤ grade 1, initiate corticosteroid taper and continue to taper over at least 1 month. Consider administration of other systemic immunosuppressants if immune-mediated adverse reaction is not controlled with corticosteroid therapy. Systemic corticosteroids may not be necessary for certain adverse reactions. Hormone replacement therapy may be required for endocrinopathies (if clinically indicated). See table for additional dosage modification guidance.</p>
<table border="1" frame="border" rules="all" style="margin-left:8em;">
<caption style="text-align:center;">
<b>Nivolumab<sup>a</sup> Recommended Dosage Modifications for Adverse Reactions</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead valign="middle">
<tr>
<th align="center">
<p style="text-indent:0em;">Adverse reaction</p></th>
<th align="center">
<p style="text-indent:0em;">Severity</p></th>
<th align="center">
<p style="text-indent:0em;">Nivolumab dosage modification</p></th></tr></thead>
<tfoot>
<tr>
<td align="center" colspan="3">
<p style="text-indent:0em;text-align:left;">
<sup>a </sup>When receiving combination therapy with nivolumab and ipilimumab, withhold or permanently discontinue both nivolumab and ipilimumab for adverse reactions meeting dosage modification recommendations. Refer to Ipilimumab monograph for information on ipilimumab dosage adjustment for toxicity.</p></td></tr></tfoot>
<tbody valign="middle">
<tr>
<td align="center" colspan="3">
<p style="text-indent:0em;">
<b>Immune-mediated adverse reactions</b></p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Cardiovascular toxicity: Myocarditis</p></td>
<td align="center">
<p style="text-indent:0em;">Grade 2, 3, or 4</p></td>
<td align="center">
<p style="text-indent:0em;">Permanently discontinue nivolumab.</p></td></tr>
<tr>
<td align="center" rowspan="3">
<p style="text-indent:0em;">Dermatologic toxicity</p></td>
<td align="center">
<p style="text-indent:0em;">Mild or moderate nonexfoliative rash</p></td>
<td align="center">
<p style="text-indent:0em;">May be managed with topical emollients and/or topical corticosteroids.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Exfoliative dermatologic conditions: Suspected Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), or drug rash with eosinophilia and systemic symptoms (DRESS)</p></td>
<td align="center">
<p style="text-indent:0em;">Withhold nivolumab.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Confirmed SJS, TEN, or DRESS</p></td>
<td align="center">
<p style="text-indent:0em;">Permanently discontinue nivolumab.</p></td></tr>
<tr>
<td align="center" rowspan="8">
<p style="text-indent:0em;">Endocrinopathies</p></td>
<td align="center">
<p style="text-indent:0em;">Grade 2</p></td>
<td align="center">
<p style="text-indent:0em;">Depending on clinical severity, consider withholding until symptom improvement with hormone replacement. Resume once acute symptoms have resolved.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Grade 3 or 4</p></td>
<td align="center">
<p style="text-indent:0em;">Withhold nivolumab until clinically stable or permanently discontinue depending on severity.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Adrenal insufficiency, ≥ grade 2</p></td>
<td align="center">
<p style="text-indent:0em;">Initiate symptomatic management (including hormone replacement as clinically indicated). Depending on the severity, withhold nivolumab.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Diabetes, type 1</p></td>
<td align="center">
<p style="text-indent:0em;">Initiate insulin as clinically indicated. Depending on the severity, withhold nivolumab.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Hypophysitis</p></td>
<td align="center">
<p style="text-indent:0em;">Withhold or discontinue nivolumab (depending on the severity). Initiate hormone replacement therapy as clinically indicated.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Hyperthyroidism</p></td>
<td align="center">
<p style="text-indent:0em;">Withhold or discontinue nivolumab (depending on the severity). Initiate medical management as clinically indicated.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Hypothyroidism</p></td>
<td align="center">
<p style="text-indent:0em;">Withhold nivolumab (depending on the severity). Initiate thyroid hormone replacement therapy as clinically indicated.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Thyroiditis</p></td>
<td align="center">
<p style="text-indent:0em;">Withhold or discontinue nivolumab (depending on the severity). Initiate medical management as clinically indicated.</p></td></tr>
<tr>
<td align="center" rowspan="4">
<p style="text-indent:0em;">GI toxicity: Colitis</p></td>
<td align="center">
<p style="text-indent:0em;">Grade 2</p></td>
<td align="center">
<p style="text-indent:0em;">Withhold therapy; resume after complete or partial (to grade 0 or 1) resolution after corticosteroid taper. Permanently discontinue therapy if no complete or partial response within 12 weeks of last treatment dose, or if unable to reduce prednisone to ≤10 mg/day (or equivalent) within 12 weeks of corticosteroid initiation.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Grade 3: Single-agent nivolumab</p></td>
<td align="center">
<p style="text-indent:0em;">Withhold nivolumab; resume nivolumab after complete or partial (to grade 0 or 1) resolution after corticosteroid taper. Permanently discontinue therapy if no complete or partial response within 12 weeks of last nivolumab dose, or if unable to reduce prednisone to ≤10 mg/day (or equivalent) within 12 weeks of corticosteroid initiation.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Grade 3: Nivolumab with ipilimumab</p></td>
<td align="center">
<p style="text-indent:0em;">Permanently discontinue.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Grade 4</p></td>
<td align="center">
<p style="text-indent:0em;">Permanently discontinue.</p></td></tr>
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;">Neurologic toxicities</p></td>
<td align="center">
<p style="text-indent:0em;">Grade 2</p></td>
<td align="center">
<p style="text-indent:0em;">Withhold nivolumab; resume nivolumab after complete or partial (to grade 0 or 1) resolution after corticosteroid taper. Permanently discontinue nivolumab if no complete or partial response within 12 weeks of last nivolumab dose, or if unable to reduce prednisone to ≤10 mg/day (or equivalent) within 12 weeks of corticosteroid initiation.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Grade 3 or 4</p></td>
<td align="center">
<p style="text-indent:0em;">Permanently discontinue nivolumab.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Ocular disorders: Vogt-Koyanagi-Harada-like syndrome</p></td>
<td align="center"></td>
<td align="center">
<p style="text-indent:0em;">May require systemic corticosteroids to reduce the risk of permanent vision loss.</p></td></tr>
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;">Pulmonary toxicity: Pneumonitis</p></td>
<td align="center">
<p style="text-indent:0em;">Grade 2</p></td>
<td align="center">
<p style="text-indent:0em;">Withhold nivolumab; resume nivolumab after complete or partial (to grade 0 or 1) resolution after corticosteroid taper. Permanently discontinue nivolumab if no complete or partial response within 12 weeks of last nivolumab dose, or if unable to reduce prednisone to ≤10 mg/day (or equivalent) within 12 weeks of corticosteroid initiation.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Grade 3 or 4</p></td>
<td align="center">
<p style="text-indent:0em;">Permanently discontinue nivolumab.</p></td></tr>
<tr>
<td align="center" colspan="3">
<p style="text-indent:0em;">
<b>Other adverse reactions</b></p></td></tr>
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;">Infusion reactions</p></td>
<td align="center">
<p style="text-indent:0em;">Grade 1 or 2</p></td>
<td align="center">
<p style="text-indent:0em;">Interrupt or slow the rate of nivolumab infusion.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Grade 3 or 4</p></td>
<td align="center">
<p style="text-indent:0em;">Permanently discontinue nivolumab.</p></td></tr></tbody></table></div>
<div class="block dorp drugH1Div" id="F51131234"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Children ≥12 years and Adolescents:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Baseline renal impairment:</i> No dosage adjustment appears necessary; eGFR ≥15 mL/minute/1.73 m<sup>2</sup> had no clinically important effect on nivolumab clearance.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Renal toxicity</i>
<b>
<i> during</i></b>
<i> treatment (nephritis or renal dysfunction): Immune</i>
<i>-mediated nephritis with kidney dysfunction:</i> If nivolumab treatment interruption or discontinuation is required, administer systemic corticosteroids (1 to 2 mg/kg/day prednisone [or equivalent]) or other appropriate therapy for immune-mediated adverse reactions until improvement to ≤ grade 1, then follow with a corticosteroid taper.</p>
<p style="text-indent:-2em;margin-left:6em;">Grade 2 or grade 3 serum creatinine elevation: Withhold nivolumab; resume nivolumab after complete or partial (to grade 0 or 1) resolution after corticosteroid taper. Permanently discontinue nivolumab if no complete or partial response within 12 weeks of last nivolumab dose, or if unable to reduce prednisone to ≤10 mg/day (or equivalent) within 12 weeks of corticosteroid initiation.</p>
<p style="text-indent:-2em;margin-left:6em;">Grade 4 serum creatinine elevation: Permanently discontinue nivolumab.</p></div>
<div class="block dohp drugH1Div" id="F51131235"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>Baseline hepatic impairment:</i> Children ≥12 years and Adolescents:</p>
<p style="text-indent:-2em;margin-left:4em;">Mild (total bilirubin ≤ ULN and AST &gt; ULN or total bilirubin &gt;1 to 1.5 times ULN and any AST) or moderate (total bilirubin &gt;1.5 to 3 times ULN and any AST) impairment: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">Severe (total bilirubin &gt;3 times ULN and any AST) impairment: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Hepatotoxicity </i>
<b>
<i>during</i></b>
<i> treatment:</i> Children ≥12 years and Adolescents:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> If nivolumab treatment interruption or discontinuation is required, administer systemic corticosteroids (1 to 2 mg/kg/day prednisone [or equivalent]) or other appropriate therapy for immune-mediated adverse reactions until improvement to ≤ grade 1, then follow with a corticosteroid taper.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Nivolumab monotherapy</i>
<i>:</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Immune-mediated hepatitis <b>without</b> tumor involvement of the liver:</i></p>
<p style="text-indent:-2em;margin-left:8em;">AST or ALT &gt;3 to ≤8 times ULN or total bilirubin &gt;1.5 to ≤3 times ULN: Withhold nivolumab treatment. Resume nivolumab treatment with complete or partial resolution (to grade 0 or 1) of hepatitis after corticosteroid taper. Permanently discontinue nivolumab if no complete or partial response within 12 weeks of last nivolumab dose, or if unable to reduce prednisone to ≤10 mg/day (or equivalent) within 12 weeks of corticosteroid initiation.</p>
<p style="text-indent:-2em;margin-left:8em;">AST or ALT &gt;8 times ULN or total bilirubin &gt;3 times ULN: Discontinue nivolumab permanently.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Immune-mediated hepatitis <b>with </b>tumor involvement of the liver:</i>
<b>Note: </b>If AST and ALT are ≤ ULN at baseline, follow recommendations for hepatitis <b>without</b> tumor involvement of the liver.</p>
<p style="text-indent:-2em;margin-left:8em;">If baseline AST or ALT &gt;1 to ≤3 times ULN and increases to &gt;5 to ≤10 times ULN or baseline AST or ALT &gt;3 to ≤5 times ULN and increases to &gt;8 to ≤10 times ULN: Withhold nivolumab treatment. Resume nivolumab treatment with complete or partial resolution (to grade 0 or 1) of hepatitis after corticosteroid taper. Permanently discontinue nivolumab if no complete or partial response within 12 weeks of last nivolumab dose, or if unable to reduce prednisone to ≤10 mg/day (or equivalent) within 12 weeks of corticosteroid initiation.</p>
<p style="text-indent:-2em;margin-left:8em;">AST or ALT increases to &gt;10 times ULN or total bilirubin increases to &gt;3 times ULN: Discontinue nivolumab permanently.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Nivolumab in combination with ipilimumab:</i>
<b>Note: </b>When receiving combination therapy with nivolumab and ipilimumab, withhold or permanently discontinue both nivolumab and ipilimumab for adverse reactions meeting dosage modification recommendations. Refer to Ipilimumab monograph for information on ipilimumab dosage adjustment for toxicity.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Immune-mediated hepatitis <b>without</b> tumor involvement of the liver or hepatitis with tumor involvement of the liver/non-hepatocellular carcinoma:</i></p>
<p style="text-indent:-2em;margin-left:8em;">AST or ALT &gt;3 to ≤5 times ULN or total bilirubin &gt;1.5 to ≤3 times ULN: Withhold treatment. Resume treatment with complete or partial resolution (to grade 0 or 1) of hepatitis after corticosteroid taper. Permanently discontinue nivolumab if no complete or partial response within 12 weeks of last nivolumab dose, or if unable to reduce prednisone to ≤10 mg/day (or equivalent) within 12 weeks of corticosteroid initiation.</p>
<p style="text-indent:-2em;margin-left:8em;">AST or ALT &gt;5 times ULN or total bilirubin &gt;3 times ULN: Discontinue permanently.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Immune-mediated hepatitis <b>with</b> tumor involvement of the liver/hepatocellular carcinoma:</i>
<b>Note: </b>If AST and ALT are ≤ ULN at baseline, follow nivolumab in combination with ipilimumab recommendations for hepatitis <b>without</b> tumor involvement of the liver.</p>
<p style="text-indent:-2em;margin-left:8em;">If baseline AST or ALT &gt;1 to ≤3 times ULN and increases to &gt;5 to ≤10 times ULN or baseline AST or ALT &gt;3 to ≤5 times ULN and increases to &gt;8 to ≤10 times ULN: Withhold treatment. Resume treatment with complete or partial resolution (to grade 0 or 1) of hepatitis after corticosteroid taper. Permanently discontinue nivolumab if no complete or partial response within 12 weeks of last nivolumab dose, or if unable to reduce prednisone to ≤10 mg/day (or equivalent) within 12 weeks of corticosteroid initiation.</p>
<p style="text-indent:-2em;margin-left:8em;">AST or ALT &gt;10 times ULN or total bilirubin &gt;3 times ULN: Discontinue permanently.</p></div>
<div class="block doa drugH1Div" id="F26827910"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="98764" href="/d/html/98764.html" rel="external">see "Nivolumab: Drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Safety:</b> Do not substitute nivolumab with nivolumab/relatlimab.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f2c27f86-343d-4fc1-b682-3d3185358f12">Colorectal cancer, metastatic, microsatellite instability-high or mismatch repair deficient</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Colorectal cancer, metastatic, microsatellite instability-high or mismatch repair deficient: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Single-agent therapy:</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> 240 <b>mg</b> once every 2 weeks <b>or</b> 480 <b>mg</b> once every 4 weeks; continue until disease progression or unacceptable toxicity.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Off-label dosing:</i>
<b>IV:</b> 3 <b>mg/kg</b> once every 2 weeks; continue until disease progression or unacceptable toxicity (Overman 2017).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Combination therapy:</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> 3 <b>mg/kg</b> once every 3 weeks (in combination with ipilimumab) for 4 combination doses, followed by nivolumab monotherapy at 240 <b>mg</b> once every 2 weeks <b>or</b> 480 <b>mg</b> once every 4 weeks; continue until disease progression or unacceptable toxicity.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Off-label dosing:</i>
<b>IV:</b> 3 <b>mg/kg</b> once every 3 weeks (in combination with ipilimumab) for 4 combination doses, followed by nivolumab monotherapy at 3 <b>mg/kg</b> once every 2 weeks; continue until disease progression or unacceptable toxicity (Overman 2018).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="35cc4e78-8966-4ebd-a4cc-1930db796186">Esophageal cancer, adenocarcinoma, advanced or metastatic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Esophageal cancer, adenocarcinoma, advanced or metastatic: IV: </b>240 <b>mg</b> once every 2 weeks <b>or </b>360 <b>mg </b>once every 3 weeks (in combination with fluoropyrimidine- and platinum-containing chemotherapy); continue until disease progression, unacceptable toxicity, or up to 2 years (Janjigian 2021).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="714db261-5bbe-4504-8847-7a1044f3e735">Esophageal cancer, squamous cell carcinoma, unresectable advanced, recurrent, or metastatic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Esophageal cancer, squamous cell carcinoma, unresectable advanced, recurrent, or metastatic:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>First-line combination therapy:</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> 240 <b>mg</b> once every 2 weeks (Doki 2022) <b>or</b> 480 <b>mg</b> once every 4 weeks (in combination with fluoropyrimidine- and platinum-containing chemotherapy); continue nivolumab until disease progression or unacceptable toxicity, or up to 2 years.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> 3 <b>mg/kg</b> once every 2 weeks (Doki 2022) <b>or</b> 360 <b>mg</b> once every 3 weeks (in combination with ipilimumab); continue until disease progression or unacceptable toxicity, or up to 2 years.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>After prior fluoropyrimidine- and platinum-based therapy:</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV</b>: 240 <b>mg</b> once every 2 weeks (Kato 2019) <b>or </b>480 <b>mg </b>once every 4 weeks; continue until disease progression or unacceptable toxicity.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4a642318-4cc5-402c-b405-886944c2434b">Esophageal or gastroesophageal junction cancer, resected, adjuvant treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Esophageal or gastroesophageal junction cancer, resected, adjuvant treatment: IV:</b> 240 <b>mg </b>once every 2 weeks <b>or </b>480 <b>mg </b>once every 4 weeks; continue until disease progression or unacceptable toxicity for up to 1 year.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Off-label dosing: </i>
<b>IV:</b> 240 <b>mg</b> once every 2 weeks for 16 weeks, followed by 480 <b>mg</b> once every 4 weeks beginning at week 17 and continuing until disease progression or unacceptable toxicity for up to 1 year (Kelly 2021).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1acd644c-933f-4a6e-9dba-66a5ef3dcf11">Gastric cancer or gastroesophageal junction cancer, advanced or metastatic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Gastric cancer or gastroesophageal junction cancer, advanced or metastatic: IV: </b>240 <b>mg</b> once every 2 weeks <b>or </b>360 <b>mg </b>once every 3 weeks (in combination with fluoropyrimidine- and platinum-containing chemotherapy); continue until disease progression, unacceptable toxicity, or up to 2 years (Janjigian 2021).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b2459ae4-1428-4e77-902f-332468c32cbb">Head and neck cancer, squamous cell carcinoma, recurrent or metastatic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Head and neck cancer, squamous cell carcinoma, recurrent or metastatic:</b>
<b>IV:</b> 240 <b>mg</b> once every 2 weeks <b>or </b>480 <b>mg </b>once every 4 weeks; continue until disease progression or unacceptable toxicity.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Off-label dosing:</i>
<b>IV: </b>3 <b>mg/kg</b> once every 2 weeks; continue until disease progression or unacceptable toxicity (Ferris 2016).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b12c5cbe-89c2-4211-ab16-15d280500cad">Hepatocellular carcinoma</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hepatocellular carcinoma:</b>
<b>IV:</b> 1 <b>mg/kg</b> once every 3 weeks (in combination with ipilimumab) for 4 combination doses, followed by nivolumab monotherapy at 240 <b>mg</b> once every 2 weeks (Yau 2020) <b>or </b>480 <b>mg</b> once every 4 weeks; continue until disease progression or unacceptable toxicity.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="777ae95c-2192-4339-afe2-a5cf337c04d1">Hodgkin lymphoma, classical</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hodgkin lymphoma, classical:</b>
<b>IV:</b> 240 <b>mg</b> once every 2 weeks <b>or </b>480 <b>mg</b> once every 4 weeks; continue until disease progression or unacceptable toxicity.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Off-label dosing:</i>
<b>IV: </b>3 <b>mg/kg</b> once every 2 weeks; continue until disease progression or unacceptable toxicity (Ansell 2015; Younes 2016).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e9d61c0f-2584-42c2-9285-79f9d2162dd1">Malignant pleural mesothelioma, unresectable</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Malignant pleural mesothelioma, unresectable (first-line therapy): IV:</b> 360 <b>mg</b> once every 3 weeks (in combination with ipilimumab); continue until disease progression, unacceptable toxicity, or for up to 2 years in patients without disease progression.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Off-label dosing:</i>
<b>IV: </b>3 <b>mg/kg</b> once every 2 weeks (in combination with ipilimumab); continue until disease progression, unacceptable toxicity, or for up to 2 years (Baas 2021; Peters 2022).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d79a7587-7a60-494c-85dd-433126853297">Melanoma, stage IIB, stage IIC, stage III, and stage IV, resected, adjuvant therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Melanoma, </b>
<b>stage IIB, stage IIC, stage III, and stage IV, resected, adjuvant therapy: IV:</b> 240 <b>mg</b> once every 2 weeks <b>or</b> 480 <b>mg </b>once every 4 weeks; continue until disease recurrence or unacceptable toxicity for up to 1 year (Kirkwood 2023; manufacturer’s labeling).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Off-label dosing:</i>
<b>IV: </b>3 <b>mg/kg</b> once every 2 weeks; continue until disease recurrence or unacceptable toxicity for up to 1 year (Ascierto 2020; Weber 2017).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5af01e42-abc4-4214-921a-a15595789572">Melanoma, metastatic with brain metastases</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Melanoma, metastatic with brain metastases (off-label use): IV:</b> 1 <b>mg/kg</b> once every 3 weeks (in combination with ipilimumab) for 4 combination doses, followed by 3 <b>mg/kg</b> once every 2 weeks (nivolumab monotherapy); total duration of nivolumab therapy is up to 24 months, or until disease progression or unacceptable toxicity (Tawbi 2018; Tawbi 2021).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5b8b61a8-a96f-4706-a076-2ede2ffc94b3">Melanoma, unresectable or metastatic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Melanoma, unresectable or metastatic:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Single-agent therapy: </i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> 240 <b>mg</b> once every 2 weeks <b>or </b>480 <b>mg</b> once every 4 weeks; continue until disease progression or unacceptable toxicity.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Off-label dosing:</i>
<b>IV: </b>3 <b>mg/kg</b> once every 2 weeks; continue until disease progression or unacceptable toxicity (Robert 2015; Weber 2015).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b></b>
<i>Combination therapy: </i></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>IV:</b> 1 <b>mg/kg</b> once every 3 weeks (in combination with ipilimumab) for a maximum of 4 combination doses or until unacceptable toxicity (whichever occurs earlier), followed by nivolumab monotherapy at 240 <b>mg</b> once every 2 weeks <b>or </b>480 <b>mg</b> once every 4 weeks; continue until disease progression or unacceptable toxicity.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Off-label dosing: </i>
<b>IV:</b> 1 <b>mg/kg</b> once every 3 weeks (in combination with ipilimumab) for 4 combination doses, followed by nivolumab monotherapy at 3 <b>mg/kg</b> once every 2 weeks; continue until disease progression or unacceptable toxicity (Larkin 2015; Larkin 2019; Wolchok 2017) <b>or </b>(alternative strategy [based on limited data]; may decrease toxicity in patients who experienced severe toxicity) 3 <b>mg/kg</b> once every 3 weeks (in combination with reduced-dose ipilimumab) for 4 combination doses, followed 6 weeks later by nivolumab monotherapy at 480 <b>mg </b>once every 4 weeks; continue until disease progression or unacceptable toxicity (Lebbé 2019).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a03fc737-51ba-437f-8914-2c99d7fee888">Merkel cell carcinoma, unresectable, recurrent, or stage IV</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Merkel cell carcinoma, unresectable, recurrent, or stage IV (off-label use): IV: </b>240 mg once every 2 weeks (in combination with ipilimumab); continue until disease progression or unacceptable toxicity (Kim 2022).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9bd3a9ec-948c-4da4-a29f-527a53d0b702">Non–small cell lung cancer, metastatic, with PD-L1 expression</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Non–small cell lung cancer, metastatic, with PD-L1 expression (≥1%): IV:</b> 360 <b>mg</b> once every 3 weeks (in combination with ipilimumab); continue until disease progression, unacceptable toxicity or for up to 2 years in patients without disease progression.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Off-label dosing:</i>
<b>IV: </b>3 <b>mg/kg</b> once every 2 weeks (in combination with ipilimumab); continue until disease progression, unacceptable toxicity, or for up to 2 years of follow up (Hellmann 2019).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a204295a-b2f0-428a-97c9-0e2bdac5af80">Non–small cell lung cancer, metastatic, relapsed or refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Non–small cell lung cancer, metastatic, relapsed or refractory:</b>
<b>IV:</b> 240 <b>mg</b> once every 2 weeks <b>or </b>480 <b>mg </b>once every 4 weeks; continue until disease progression or unacceptable toxicity.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Off-label dosing:</i>
<b>IV: </b>3 <b>mg/kg</b> once every 2 weeks; continue until disease progression or unacceptable toxicity (Borghaei 2015; Brahmer 2015).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f255d5ce-fe57-463a-a9be-47206170344c">Non–small cell lung cancer, metastatic or recurrent</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Non–small cell lung cancer, metastatic or recurrent: </b>IV: 360 <b>mg</b> once every 3 weeks (in combination with ipilimumab and 2 cycles of histology-based platinum-doublet chemotherapy); continue until disease progression, unacceptable toxicity or for up to 2 years in patients without disease progression (Paz-Ares 2021).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c6f2c666-b6b6-447a-b370-c92e591603c8">Non–small cell lung cancer, resectable, neoadjuvant therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Non–small cell lung cancer, resectable, neoadjuvant therapy: IV:</b> 360 <b>mg</b> once every 3 weeks (in combination with histology-based platinum-doublet chemotherapy) for 3 cycles (Forde 2022).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9cada6c3-01ad-4226-90a9-a0809abeba8f">Renal cell carcinoma, advanced, first-line single-agent therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Renal cell carcinoma, advanced, first-line single-agent therapy (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>May be used as monotherapy in patients with limited burden, favorable-risk disease when ipilimumab-based regimens or antiangiogenic agents are not appropriate options (ASCO [Rathmell 2022]; Atkins 2022a; George 2022).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV: </b>240 <b>mg</b> once every 2 weeks <b>or</b> 480 <b>mg</b> once every 4 weeks; continue until disease progression, unacceptable toxicity, or (in patients without disease recurrence) up to 96 weeks (Atkins 2022b).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="01ba1574-d28e-491e-b878-10259e42f21d">Renal cell carcinoma, advanced, first-line combination therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Renal cell carcinoma, advanced, first-line combination therapy:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>May be used in combination with cabozantinib regardless of risk stratification (Choueiri 2021). May be used in combination with ipilimumab in patients with intermediate- or poor-risk disease, and the ipilimumab combination may also be considered (off label) in patients with favorable-risk disease (ASCO [Rathmell 2022]; Atkins 2022a; George 2022; Motzer 2019).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>In combination with cabozantinib: </i>
<b>IV: </b>240 <b>mg</b> once every 2 weeks (Choueiri 2021) <b>or </b>480 <b>mg </b>once every 4 weeks; continue until disease progression, unacceptable toxicity, or (in patients without disease progression) for up to 2 years.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>In combination with ipilimumab:</i>
<b>IV:</b> 3 <b>mg/kg</b> once every 3 weeks for 4 combination doses, followed by nivolumab monotherapy administered either as 240 <b>mg</b> once every 2 weeks (Motzer 2019) <b>or</b> 480 <b>mg</b> once every 4 weeks; continue until disease progression, unacceptable toxicity, or (in patients without disease progression) for up to 2 years.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Off-label dosing:</i>
<b>IV: </b>3 <b>mg/kg</b> once every 3 weeks (in combination with ipilimumab) for 4 combination doses, followed by 3 <b>mg/kg</b> once every 2 weeks (nivolumab monotherapy); continue until disease progression or unacceptable toxicity (Motzer 2018; Motzer 2019).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="76924426-cfe6-4f52-93b1-a915f71827e2">Renal cell carcinoma, advanced, previously treated, single-agent therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Renal cell carcinoma, advanced, previously treated, single-agent therapy: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>May be used in patients with progression on initial treatment with an antiangiogenic agent (Motzer 2015; Motzer 2020).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV</b>: 240 <b>mg</b> once every 2 weeks <b>or </b>480 <b>mg </b>once every 4 weeks (as a single agent); continue until disease progression or unacceptable toxicity.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Off-label dosing:</i>
<b>IV: </b>3 <b>mg/kg</b> once every 2 weeks (as a single agent); continue until disease progression or unacceptable toxicity (Motzer 2015; Motzer 2020).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0a153f3d-57a5-497a-8485-49a0c4d586ab">Urothelial carcinoma, resected, adjuvant therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Urothelial carcinoma, resected, adjuvant therapy: IV:</b> 240 <b>mg</b> once every 2 weeks (Bajorin 2021) <b>or</b> 480 <b>mg </b>once every 4 weeks; continue until disease recurrence or unacceptable toxicity for up to 1 year.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e18ba80f-c114-4a29-a182-da5fe7eb51f6">Urothelial carcinoma, locally advanced or metastatic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Urothelial carcinoma, locally advanced or metastatic: IV:</b> 240 <b>mg</b> once every 2 weeks <b>or </b>480 <b>mg </b>once every 4 weeks; continue until disease progression or unacceptable toxicity.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Off-label dosing:</i>
<b>IV: </b>3 <b>mg/kg</b> once every 2 weeks; continue until disease progression or unacceptable toxicity (Sharma 2017).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991167"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Kidney impairment <b>prior</b> to treatment initiation:</i></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Altered kidney function:</b> No dosage adjustment likely for any degree of kidney dysfunction (Bajaj 2017; expert opinion).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Unlikely to be significantly dialyzable (large molecular weight): No supplemental dose or dosage adjustment necessary (Ansari 2018; Carlo 2016; Cheun 2019; Hirsch 2020; Klajer 2020; Osmán-García 2020; Shaw 2021; Tabei 2017; Vitale 2019; expert opinion).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Peritoneal dialysis:</b> Unlikely to be significantly dialyzable (large molecular weight): No dosage adjustment necessary (Hirsch 2020; Osmán-García 2020; Vitale 2019; expert opinion).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>CRRT:</b> No dosage adjustment necessary (expert opinion).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b> No dosage adjustment necessary (expert opinion).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Kidney toxicity</i>
<b>
<i> during</i></b>
<i> treatment:</i></p>
<p style="text-indent:0em;margin-left:2em;">
<i>Immune-mediated nephritis with kidney dysfunction: </i>If nivolumab treatment interruption or discontinuation is required, administer systemic corticosteroids (1 to 2 mg/kg/day prednisone [or equivalent]) or other appropriate therapy for immune-mediated adverse reactions until improvement to ≤ grade 1, then follow with a corticosteroid taper.</p>
<p style="text-indent:0em;margin-left:4em;">Grade 2 or grade 3 serum creatinine elevation: Withhold nivolumab; resume nivolumab after complete or partial (to grade 0 or 1) resolution after corticosteroid taper. Permanently discontinue nivolumab if no complete or partial response within 12 weeks of last nivolumab dose, or if unable to reduce prednisone to ≤10 mg/day (or equivalent) within 12 weeks of corticosteroid initiation.</p>
<p style="text-indent:0em;margin-left:4em;">Grade 4 serum creatinine elevation: Permanently discontinue nivolumab.</p></div>
<div class="block doha drugH1Div" id="F50988530"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>Hepatic impairment <b>prior to</b> treatment initiation:</i></p>
<p style="text-indent:-2em;margin-left:4em;">Mild (total bilirubin ≤ ULN and AST &gt; ULN or total bilirubin &gt;1 to 1.5 × ULN and any AST) or moderate (total bilirubin &gt;1.5 to 3 × ULN and any AST) impairment: There are no dosage adjustments provided in the manufacturer's labeling; however, mild or moderate impairment had no clinically important effect on nivolumab clearance.</p>
<p style="text-indent:-2em;margin-left:4em;">Severe (total bilirubin &gt;3 × ULN and any AST) impairment: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Hepatotoxicity</i>
<b>
<i> during</i></b>
<i> treatment: </i></p>
<p style="text-indent:-2em;margin-left:4em;">If nivolumab treatment interruption or discontinuation is required, administer systemic corticosteroids (1 to 2 mg/kg/day prednisone [or equivalent]) or other appropriate therapy for immune-mediated adverse reactions until improvement to ≤ grade 1, then follow with a corticosteroid taper. Permanently discontinue nivolumab if no complete or partial response within 12 weeks of last nivolumab dose, or if unable to reduce prednisone to ≤10 mg/day (or equivalent) within 12 weeks of corticosteroid initiation.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Nivolumab monotherapy:</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Immune-mediated hepatitis <b>without</b> tumor involvement of the liver:</i></p>
<p style="text-indent:-2em;margin-left:8em;">AST or ALT &gt;3 to ≤8 × ULN or total bilirubin &gt;1.5 to ≤3 × ULN: Withhold nivolumab treatment. Resume nivolumab treatment with complete or partial resolution (to grade 0 or 1) of hepatitis after corticosteroid taper.</p>
<p style="text-indent:-2em;margin-left:8em;">AST or ALT &gt;8 × ULN or total bilirubin &gt;3 × ULN: Discontinue nivolumab permanently.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Immune-mediated hepatitis <b>with </b>tumor involvement of the liver:</i>
<b>Note: </b>If AST and ALT are ≤ ULN at baseline, follow recommendations for hepatitis <b>without</b> tumor involvement of the liver.</p>
<p style="text-indent:-2em;margin-left:8em;">If baseline AST or ALT &gt;1 to ≤3 × ULN and increases to &gt;5 to ≤10 × ULN or baseline AST or ALT &gt;3 to ≤5 × ULN and increases to &gt;8 to ≤10 × ULN: Withhold nivolumab treatment. Resume nivolumab treatment with complete or partial resolution (to grade 0 or 1) of hepatitis after corticosteroid taper.</p>
<p style="text-indent:-2em;margin-left:8em;">AST or ALT increases to &gt;10 × ULN or total bilirubin increases to &gt;3 × ULN: Discontinue nivolumab permanently.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Nivolumab in combination with ipilimumab:</i>
<b>Note: </b>When receiving combination therapy with nivolumab and ipilimumab, withhold or permanently discontinue both nivolumab and ipilimumab for adverse reactions meeting dosage modification recommendations. Refer to Ipilimumab monograph for information on ipilimumab dosage adjustment for toxicity.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Immune-mediated hepatitis <b>without</b> tumor involvement of the liver <b>or</b> hepatitis with tumor involvement of the liver/non-hepatocellular carcinoma:</i></p>
<p style="text-indent:-2em;margin-left:8em;">AST or ALT &gt;3 to ≤5 × ULN or total bilirubin ≥1.5 to ≤3 × ULN: Withhold treatment. Resume treatment with complete or partial resolution (to grade 0 or 1) of hepatitis after corticosteroid taper.</p>
<p style="text-indent:-2em;margin-left:8em;">AST or ALT &gt;5 × ULN or total bilirubin &gt;3 × ULN: Discontinue permanently.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Immune-mediated hepatitis <b>with</b> tumor involvement of the liver/hepatocellular carcinoma:</i>
<b>Note: </b>If AST and ALT are ≤ ULN at baseline, follow nivolumab in combination with ipilimumab recommendations for hepatitis <b>without</b> tumor involvement of the liver.</p>
<p style="text-indent:-2em;margin-left:8em;">If baseline AST or ALT &gt;1 to ≤3 × ULN and increases to &gt;5 to ≤10 × ULN or baseline AST or ALT &gt;3 to ≤5 × ULN and increases to &gt;8 to ≤10 × ULN: Withhold treatment. Resume treatment with complete or partial resolution (to grade 0 or 1) of hepatitis after corticosteroid taper.</p>
<p style="text-indent:-2em;margin-left:8em;">AST or ALT &gt;10 × ULN or total bilirubin &gt;3 × ULN: Discontinue permanently.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Nivolumab in combination with cabozantinib:</i>
<b>Note: </b>Refer to Cabozantinib monograph for information on cabozantinib dosage adjustment for toxicity. For liver enzyme elevations when administered in combination with cabozantinib, consider corticosteroid therapy if nivolumab and/or cabozantinib is withheld or discontinued.</p>
<p style="text-indent:-2em;margin-left:6em;">ALT or AST &gt;3 to ≤10 × ULN with concurrent total bilirubin &lt;2 × ULN: Withhold both nivolumab and cabozantinib. Upon recovery to grade 0 or 1, may consider rechallenging with nivolumab and/or cabozantinib.</p>
<p style="text-indent:-2em;margin-left:6em;">ALT or AST &gt;10 × ULN or &gt;3 × ULN with concurrent total bilirubin ≥2 × ULN: Permanently discontinue both nivolumab and cabozantinib.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Additional</i>
<i> recommendations:</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Grade 2 immune-mediated hepatitis:</i> Withhold immune checkpoint inhibitor (ICI); if no improvement within 3 to 5 days after ICI is withheld, consider initiation of corticosteroids (prednisone 0.5 to 1 mg/kg/day or equivalent) (ASCO [Schneider 2021]).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Grade 3 or 4 immune-mediated hepatitis:</i> Withhold ICI; initiate corticosteroids (methylprednisolone 1 to 2 mg/kg or equivalent) (ASCO [Schneider 2021]). Based on data from a retrospective cohort study in patients with grade 3 or 4 immune-mediated hepatitis, initial treatment with methylprednisolone 1 mg/kg/day demonstrated similar time to ALT normalization (compared with higher methylprednisolone doses), while reducing the potential for corticosteroid-related complications (Li 2022).</p></div>
<div class="block arsc drugH1Div" id="F55608264"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Cardiovascular toxicity</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute coronary syndrome</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31382863','lexi-content-ref-28651328']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31382863','lexi-content-ref-28651328'])">Ref</a></span>),<b> vasculitis</b>, immune-mediated<b> myocarditis</b>, and <b>pericarditis</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29461982']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29461982'])">Ref</a></span>) have rarely occurred. Cardiovascular events are potentially fatal (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31189042','lexi-content-ref-29536852']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31189042','lexi-content-ref-29536852'])">Ref</a></span>). Myocarditis and pericarditis may overlap with <b>myositis</b> and <b>myasthenia gravis</b> in patients receiving immune checkpoint inhibitors. Death occurred in 46% of patients with severe myocarditis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29536852']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29536852'])">Ref</a></span>). Vasculitis has been reported in large, medium, and small vessels as well as the CNS (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34172516']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34172516'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Non–dose-related; exact mechanism is unknown. Evolving data suggest the presence of common high frequency T‐cell receptors in cardiac muscle (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29802219','lexi-content-ref-27806233']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29802219','lexi-content-ref-27806233'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; median reported onset of myocarditis is ~30 to 65 days, with most cases occurring in the first 3 months of treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29158217','lexi-content-ref-29802219','lexi-content-ref-29567210']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29158217','lexi-content-ref-29802219','lexi-content-ref-29567210'])">Ref</a></span>). Late presentations of up to 454 days have also been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29158217']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29158217'])">Ref</a></span>). Median onset of vasculitis is 3 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34172516']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34172516'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Autoimmune disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26633184','lexi-content-ref-28241095','lexi-content-ref-29320654']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26633184','lexi-content-ref-28241095','lexi-content-ref-29320654'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Diabetes mellitus (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29567210']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29567210'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Combination therapy with anti-PD-1/PD-L1 plus anti-CTLA-4 (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29536852']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29536852'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Preexisting cardiovascular disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29567210']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29567210'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Dermatologic toxicity</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Immune-mediated rashes, including <b>Stevens-Johnson syndrome </b>(SJS) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30782092','lexi-content-ref-29045532','lexi-content-ref-31290394']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30782092','lexi-content-ref-29045532','lexi-content-ref-31290394'])">Ref</a></span>),<b> toxic epidermal necrolysis</b> ([TEN] some fatal) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32281097','lexi-content-ref-29687056','lexi-content-ref-26938948']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32281097','lexi-content-ref-29687056','lexi-content-ref-26938948'])">Ref</a></span>), exfoliative dermatitis, and <b>bullous pemphigoid </b>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30018132','lexi-content-ref-30268391']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30018132','lexi-content-ref-30268391'])">Ref</a></span>) may occur with nivolumab (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29442540','lexi-content-ref-26371282']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29442540','lexi-content-ref-26371282'])">Ref</a></span>). Among the diverse immune-related adverse events (irAEs), cutaneous toxicities, such as <b>skin <b>rash</b></b>, <b>pruritus</b>, and <b>vitiligo</b>, are by far the most common and the earliest to occur (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29442540','lexi-content-ref-26629425']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29442540','lexi-content-ref-26629425'])">Ref</a></span>); however, rarer rashes, such as lichenoid (eg, lichenoid dermatitis), and bullous disorders, including bullous pemphigoid, SJS, and TEN, are of special interest due to their severity and potentially life-threatening consequences (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26371282']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26371282'])">Ref</a></span>). Additional reported mucosal toxicities include <b>stomatitis</b>, gingivitis, and <b>Sjögren</b>
<b>disease</b>-like symptoms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27367787','lexi-content-ref-34172516']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27367787','lexi-content-ref-34172516'])">Ref</a></span>). Although most cutaneous toxicities are transient, they can cause significant morbidity and impairment of patients’ health-related quality of life; some adverse reactions (eg, Sjögren disease) may not fully resolve, necessitating long-term treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29442540','lexi-content-ref-34172516','lexi-content-ref-26629425']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29442540','lexi-content-ref-34172516','lexi-content-ref-26629425'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Non–dose-related; exact mechanism unknown. May involve blockade of a common antigen (co-expressed on a patient's tumor cells and those of the dermo-epidermal junction and/or other levels of the skin) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26371282']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26371282'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Intermediate; for most patients, dermatologic toxicity is the earliest irAE experienced and has been reported with nivolumab at a median onset ranging from 2.8 to 6.1 weeks (range: &lt;1 day to 25.8 months) after treatment initiation and may occur in patients with any tumor type (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27367787','lexi-content-ref-29951303','lexi-content-ref-34724392','lexi-content-ref-34172516']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27367787','lexi-content-ref-29951303','lexi-content-ref-34724392','lexi-content-ref-34172516'])">Ref</a></span>). Median time to onset for Sjögren disease-like symptoms is 70 days ((<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34172516']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34172516'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Endocrine toxicity</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Endocrine toxicities include primary <b>hypothyroidism</b>, <b>hyperthyroidism</b>, <b>adrenocortical insufficiency</b> (primary and secondary), <b>hypophysitis</b> (inflammation of the pituitary gland), and <b>type 1 diabetes mellitus</b> (including <b>diabetic ketoacidosis</b>) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29442540','lexi-content-ref-28881921','lexi-content-ref-26027431','lexi-content-ref-34172516','lexi-content-ref-22614989']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29442540','lexi-content-ref-28881921','lexi-content-ref-26027431','lexi-content-ref-34172516','lexi-content-ref-22614989'])">Ref</a></span>). In rare cases, patients may present with adrenal crisis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26371282']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26371282'])">Ref</a></span>). Hypothyroidism and hyperthyroidism are frequently asymptomatic (or present with vague symptoms) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34172516']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34172516'])">Ref</a></span>). Immune-mediated endocrinopathies usually require permanent hormone replacement (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27367787','lexi-content-ref-34172516']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27367787','lexi-content-ref-34172516'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Non–dose-related; mechanisms not fully understood. Thyroid dysfunction may be due to the development of antithyroglobulin or antithyroid peroxidase antibodies. In rare cases, Graves disease may arise due to the development of anti-thyroid-stimulating hormone receptor antibodies (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26371282']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26371282'])">Ref</a></span>). Hypophysitis may be due to humoral immunity against the pituitary gland, with involvement of the complement system (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26371282']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26371282'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; often delayed and can appear at any time throughout treatment with immune checkpoint inhibitors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29442540','lexi-content-ref-28881921','lexi-content-ref-26027431','lexi-content-ref-22614989']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29442540','lexi-content-ref-28881921','lexi-content-ref-26027431','lexi-content-ref-22614989'])">Ref</a></span>). Adrenal insufficiency: Median onset of 10 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34172516']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34172516'])">Ref</a></span>). Hypophysitis: Median onset of 76 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34172516']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34172516'])">Ref</a></span>). Hypothyroidism: Median onset of 10 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34172516']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34172516'])">Ref</a></span>). Diabetes mellitus: Median onset of 4.4 months (range: 15 days to 22 months). Thyrotoxicosis: Median onset of 5 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34172516']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34172516'])">Ref</a></span>). Type 1 diabetes mellitus: Up to a year after initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34172516']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34172516'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Autoimmune disorders (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28228726']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28228726'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Combination therapy with anti-PD-1/PD-L1 plus anti-CTLA-4 (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28973656']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28973656'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">GI toxicity</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Immune-mediated <b>colitis</b> has occurred, including cases of grade 2 to 4 colitis.<b> Diarrhea</b> and colitis represent a clinical spectrum in which diarrhea is defined as increased stool frequency and colitis involves symptoms of <b>abdominal pain</b> and either clinical or radiologic evidence of colonic inflammation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26371282','lexi-content-ref-25918278']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26371282','lexi-content-ref-25918278'])">Ref</a></span>). Colitis affecting the descending colon is one of the most common complications leading to hospitalization and increased morbidity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18545145']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18545145'])">Ref</a></span>). Enteritis with small bowel obstruction has been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28228726','lexi-content-ref-31823117']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28228726','lexi-content-ref-31823117'])">Ref</a></span>). Complications, such as <b>intestinal perforation</b>, ischemia, necrosis, bleeding, and toxic megacolon may occur (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34172516','lexi-content-ref-31823117']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34172516','lexi-content-ref-31823117'])">Ref</a></span>). Colitis-related mortality is associated with delayed reporting, noncompliance with an antidiarrheal regimen, and delays in drug withholding (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28228726','lexi-content-ref-26371282']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28228726','lexi-content-ref-26371282'])">Ref</a></span>). In a retrospective study, when re-challenged, up to 34% of patients experienced a recurrence of colitis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34172516']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34172516'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Non–dose-related; immunologic (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28228726','lexi-content-ref-26371282']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28228726','lexi-content-ref-26371282'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; median onset of 5 to 10 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28228726','lexi-content-ref-34724392','lexi-content-ref-34172516']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28228726','lexi-content-ref-34724392','lexi-content-ref-34172516'])">Ref</a></span>). Median onset with nivolumab has been reported at 4.9 weeks to 5.3 months (range: &lt;1 day to 22.75 months) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29951303']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29951303'])">Ref</a></span>). Nivolumab plus ipilimumab combination median onset of colitis ranges from 1.6 to 2.4 months (range: 2 days to 19.2 months).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Autoimmune disorders of the GI tract (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28228726','lexi-content-ref-34172516']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28228726','lexi-content-ref-34172516'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Combination therapy with anti-PD-(L)1 inhibitors and anti-CTLA-4 inhibitors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34172516']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34172516'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Gut microbiome (bacteria of the phylum Firmicutes) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34172516']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34172516'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Prior treatment with NSAIDs (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34172516']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34172516'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hematologic toxicity</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Hematologic immune-related adverse events occur less frequently. Severity varies from mild, asymptomatic cytopenias to more significant reports of <b>immune thrombocytopenia</b>, <b>autoimmune hemolytic anemia </b>(AIHA), <b>acquired blood coagulation disorder</b> (hemophilia) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31311716','lexi-content-ref-30017828']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31311716','lexi-content-ref-30017828'])">Ref</a></span>), and <b>disseminated intravascular coagulation</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29442540','lexi-content-ref-27367787','lexi-content-ref-32275077','lexi-content-ref-30347480']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29442540','lexi-content-ref-27367787','lexi-content-ref-32275077','lexi-content-ref-30347480'])">Ref</a></span>). Development of higher grades of <b>anemia</b> have led to treatment discontinuation in a small percentage of patients treated for head and neck cancers, urothelial and cervical cancer, and non-small cell lung cancer (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27367787']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27367787'])">Ref</a></span>). Although the incidence for AIHA is rare, it can result in fatalities (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30347480']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30347480'])">Ref</a></span>). AIHA was significantly more common with anti-PD-1/PD-L1 monoclonal antibodies (ie, nivolumab, pembrolizumab, atezolizumab) than with anti-CTLA-4 monoclonal antibodies (ie, ipilimumab) in a review of 68 case reports (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30347480']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30347480'])">Ref</a></span>). Several cases of autoimmune <b>pure red cell aplasia</b>, <b>neutropenia</b>, thrombocytopenia, and even <b>pancytopenia</b> have also been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34172516','lexi-content-ref-30347480','lexi-content-ref-32270507']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34172516','lexi-content-ref-30347480','lexi-content-ref-32270507'])">Ref</a></span>). <b>Hemophagocytic lymphohistiocytosis</b> has been reported in patients receiving immunotherapy with nivolumab plus ipilimumab (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31129384','lexi-content-ref-30012206','lexi-content-ref-29472154']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31129384','lexi-content-ref-30012206','lexi-content-ref-29472154'])">Ref</a></span>). This is a rare but potentially fatal syndrome of excessive immune activation, resulting in multiorgan failure, including cytopenias and bleeding (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31046841']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31046841'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Non–dose-related; exact mechanism unknown. AIHA may be a result of augmenting or redirecting patients' immune surveillance. In addition, it is speculated that the random activation of the immune system results in the formation of autoantibodies, activation of T‐cell clones, and the lessening of regulatory T-cell function (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30347480']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30347480'])">Ref</a></span>). This is different from other drug-induced AIHA in which a drug is absorbed to the red blood cell membrane and triggers the development of autoantibodies to the red cell membrane (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30347480']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30347480'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; AIHA occurred between 2 and 78 weeks with a median of 10 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30347480']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30347480'])">Ref</a></span>). Median time to onset has been reported: Neutropenia (10 weeks), autoimmune hemolytic anemia (3.9 weeks), pancytopenia or aplastic anemia (21.7 weeks) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30528137']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30528137'])">Ref</a></span>); hemophagocytic lymphohistiocytosis (26 days), immune thrombocytopenia (41 days), pure red cell aplasia (89 days) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34172516']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34172516'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Combination immunotherapy and chemotherapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30347480']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30347480'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Combination therapy with anti-PD-1/PD-L1 plus anti-CTLA-4 (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30012206','lexi-content-ref-32191382','lexi-content-ref-29472154']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30012206','lexi-content-ref-32191382','lexi-content-ref-29472154'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hepatotoxicity</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Immune-mediated <b>hepatitis</b> (grades 2 to 4) may occur with nivolumab. Hepatitis is associated with <b>increased serum aspartate transaminase</b>, <b>increased serum alanine transaminase</b>, and occasionally <b>increased serum bilirubin</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26027431','lexi-content-ref-29603856','lexi-content-ref-31309615']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26027431','lexi-content-ref-29603856','lexi-content-ref-31309615'])">Ref</a></span>). Although clinically significant hepatotoxicity occurs infrequently, fatal immune-related liver injury has been observed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26027431','lexi-content-ref-29603856']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26027431','lexi-content-ref-29603856'])">Ref</a></span>). Hepatoxicity typically involves a hepatocellular or cholestatic pattern of injury and can range from mild laboratory findings to acute liver failure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28476244','lexi-content-ref-33929376','lexi-content-ref-29603856']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28476244','lexi-content-ref-33929376','lexi-content-ref-29603856'])">Ref</a></span>). Immune-mediated hepatitis ranges in severity from mild to life-threatening and has both similarities and differences with idiopathic autoimmune hepatitis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29603856']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29603856'])">Ref</a></span>). The incidence of immune-mediated hepatotoxic effects is lower in patients treated with anti- PD-1 monoclonal antibodies like nivolumab in comparison to those treated with anti‐CTLA‐4 monoclonal antibodies (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28228726']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28228726'])">Ref</a></span>). Most studies have demonstrated a higher incidence of liver injury in patients treated with combination regimens of anti‐CTLA‐4 and anti‐PD-1/PD-L1 therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28228726','lexi-content-ref-29603856']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28228726','lexi-content-ref-29603856'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Possibly dose- and time-related; immunologic (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28550712','lexi-content-ref-31309615']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28550712','lexi-content-ref-31309615'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; hepatotoxicity typically occurs within 1 to 15 weeks but may be delayed by months or years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34172516']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34172516'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Cumulative dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29603856']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29603856'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Preexisting autoimmune diathesis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29603856']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29603856'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Chronic infection (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29603856']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29603856'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Tumor infiltration of the liver parenchyma (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29603856']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29603856'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Combinations of nivolumab with a second immune checkpoint inhibitor or other antineoplastic agents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27141885']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27141885'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Autoimmune liver injury (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27141885']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27141885'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Prior exposure to chemotherapy, radiation therapy, transarterial chemoembolization, or radioembolization (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31309615']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31309615'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Nephrotoxicity</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Immune-mediated <b>nephritis</b> has rarely occurred. Although an <b>increased serum creatinine</b> is common, <b>acute kidney injury</b> occurs less frequently (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27282937','lexi-content-ref-28228726']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27282937','lexi-content-ref-28228726'])">Ref</a></span>) and may manifest as acute tubular necrosis, autoimmune reactivation of <b>membranous glomerulonephritis</b>, glomerular disease, prerenal disease, or tubulointerstitial nephritis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34172516']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34172516'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Non–dose-related; immunologic (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27282937']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27282937'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied. Increase in serum creatinine occurs 12 to 48 weeks after initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28228726','lexi-content-ref-30865922']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28228726','lexi-content-ref-30865922'])">Ref</a></span>). Acute kidney injury: Median onset of 13 weeks; case reports of earlier onset of 3 weeks after initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27282937']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27282937'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Neurologic toxicity</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Neurologic toxicity is rare and has been reported with use of nivolumab alone, in combination with ipilimumab, or in combination with chemotherapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28228726']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28228726'])">Ref</a></span>). These include <b>cerebral hemorrhage</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31647029']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31647029'])">Ref</a></span>), confusion, <b>myasthenia gravis</b>, and <b>reversible posterior leukoencephalopathy syndrome</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29620070','lexi-content-ref-31110718','lexi-content-ref-28228726','lexi-content-ref-26371282','lexi-content-ref-28426103']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29620070','lexi-content-ref-31110718','lexi-content-ref-28228726','lexi-content-ref-26371282','lexi-content-ref-28426103'])">Ref</a></span>). More common peripheral nervous adverse reactions include <b>myasthenia gravis</b>, <b>peripheral neuropathy</b>, and <b>Guillain-Barre syndrome</b>. More common CNS reactions include<b> aseptic meningitis</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31998480','lexi-content-ref-31700625']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31998480','lexi-content-ref-31700625'])">Ref</a></span>), <b>encephalitis</b>, and transverse myelitis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28426103']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28426103'])">Ref</a></span>). Isolated cases of myasthenia gravis have been reported in studies combining anti-PD-1/PD-L1 with anti-CTLA-4 monoclonal antibodies (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26371282']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26371282'])">Ref</a></span>). Neurologic toxicity may be fatal or cause permanent impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34172516']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34172516'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Varied; typically develop within 3 to 4 months of initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34724392','lexi-content-ref-34172516','lexi-content-ref-28426103']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34724392','lexi-content-ref-34172516','lexi-content-ref-28426103'])">Ref</a></span>). Guillain-Barre syndrome: Onset typically within the first 3 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34172516']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34172516'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Ophthalmic toxicity</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Uveitis</b> (anterior, posterior, or panuveitis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34172516']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34172516'])">Ref</a></span>) has been reported in patients receiving both single agent and combination anti-PD-1 and anti-CTLA-4 monoclonal antibodies (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26371282','lexi-content-ref-25891173']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26371282','lexi-content-ref-25891173'])">Ref</a></span>). Other ocular events reported include blurred vision, <b>dry eye syndrome</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34172516']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34172516'])">Ref</a></span>), color changes, <b>blepharoptosis</b>, inflammation of the eyelid<b>, keratitis</b>, ocular myasthenia, <b>Vogt-Koyanagi-Harada disease</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27649838']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27649838'])">Ref</a></span>), and photophobia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28856338','lexi-content-ref-29594059','lexi-content-ref-30627102','lexi-content-ref-32301024','lexi-content-ref-30865922','lexi-content-ref-27084345']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28856338','lexi-content-ref-29594059','lexi-content-ref-30627102','lexi-content-ref-32301024','lexi-content-ref-30865922','lexi-content-ref-27084345'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Varied; median onset of 5 weeks (range: 1 to 72 weeks) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34724392']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34724392'])">Ref</a></span>) .</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Pulmonary toxicity</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Immune-mediated <b>pneumonitis</b> has occurred less frequently, including grade 3 and 4 and fatal cases. A higher incidence was observed in patients who received combination therapy and patients treated with combination immunotherapy may be less likely to experience resolution of the immune-related adverse event compared with patients with monotherapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29442540']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29442540'])">Ref</a></span>). Recurrent pneumonitis following resolution of symptoms has occurred in patients who were re-challenged with immune checkpoint inhibitor therapy and in patients who were not re-challenged; chronic courses may also occur (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34172516']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34172516'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Non–dose-related; immunologic (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29442540']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29442540'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; ranging from 2 to 24 months with a median onset of ~3 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29442540']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29442540'])">Ref</a></span>). The median time to development was 3.5 months (range: 1 day to 22.3 months). Onset can occur earlier with combination therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29442540']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29442540'])">Ref</a></span>). In combination with ipilimumab, median onset ranged from 1.6 to 2.6 months (range: 8 days to 10.1 months).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Combination therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29442540']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29442540'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Prior thoracic radiation in non-small cell lung cancer patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29442540']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29442540'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Treatment-naive patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28499515']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28499515'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Asthma and/or smoking (higher grade) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34172516']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34172516'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Treatment for non-small cell lung cancer or renal cell carcinoma (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34172516']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34172516'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F27160901"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Incidence of adverse reactions includes unapproved dosing regimens. Reported adverse reactions are for adults.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Edema (12%), hypertension (11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pruritus (13% to 30%)<span class="lexi-table-link-container"> (<a aria-label="Pruritus table link" class="lexi-table-link" data-table-id="lexi-content-pruritus" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-pruritus')">table 1</a>)</span><span class="table-link" style="display:none;">Pruritus</span>, skin rash (21% to 40%)<span class="lexi-table-link-container"> (<a aria-label="Skin Rash table link" class="lexi-table-link" data-table-id="lexi-content-skin-rash" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-skin-rash')">table 2</a>)</span><span class="table-link" style="display:none;">Skin Rash</span>, vitiligo (10% to 11%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Pruritus" frame="border" id="lexi-content-pruritus" rules="all">
<caption style="text-align:center;">
<b>Nivolumab: Adverse Reaction: Pruritus</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Nivolumab)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comparator</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Nivolumab)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Comparator)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">13%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">240 mg IV infused over 30 minutes once every 2 weeks x 16 weeks; followed by 480 mg infused over 30 minutes every 4 weeks beginning on week 17</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adjunctive treatment of resected esophageal or gastroesophageal junction cancer</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">532</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">260</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">28%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Ipilimumab: 37%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3 mg/kg over 60 minutes every 2 weeks</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adjuvant treatment of melanoma</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">452</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">453</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">20%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">11%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">480 mg IV over 30 min once every 4 weeks</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adjuvant treatment of melanoma</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">524</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">264</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">30%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">16%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">240 mg over 30 minutes every 2 weeks</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adjuvant treatment of urothelial carcinoma</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">351</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">348</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">23%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Dacarbazine: 12%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3 mg/kg over 60 minutes every 2 weeks</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Previously untreated metastatic melanoma</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">206</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">205</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Skin Rash" frame="border" id="lexi-content-skin-rash" rules="all">
<caption style="text-align:center;">
<b>Nivolumab: Adverse Reaction: Skin Rash</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Nivolumab)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comparator </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Nivolumab)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Comparator)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">21%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">10%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">240 mg IV infused over 30 minutes once every 2 weeks x 16 weeks; followed by 480 mg infused over 30 minutes every 4 weeks beginning on week 17</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adjunctive treatment of resected esophageal or gastroesophageal junction cancer</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">532</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">260</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">35%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Ipilimumab: 47%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3 mg/kg over 60 minutes every 2 weeks</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adjuvant treatment of melanoma</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">452</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">453</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">28%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">15%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">480 mg IV over 30 min once every 4 weeks</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adjuvant treatment of melanoma</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">524</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">264</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">36%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">19%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">240 mg over 30 minutes every 2 weeks</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adjuvant treatment of urothelial carcinoma</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">351</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">348</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">40%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Ipilimumab: 42%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3 mg/kg over 60 minutes every 2 weeks</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Previously untreated metastatic melanoma</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">313</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">311</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">28%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Dacarbazine: 12%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3 mg/kg over 60 minutes every 2 weeks</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Previously untreated metastatic melanoma</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">206</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">205</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hypercalcemia (12%), hyperglycemia (46%), hyperkalemia (12% to 32%), hyperthyroidism (6% to 11%)<span class="lexi-table-link-container"> (<a aria-label="Hyperthyroidism table link" class="lexi-table-link" data-table-id="lexi-content-hyperthyroidism" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-hyperthyroidism')">table 3</a>)</span><span class="table-link" style="display:none;">Hyperthyroidism</span>, hypocalcemia (10% to 17%), hypokalemia (12%), hypomagnesemia (16%), hyponatremia (16% to 22%), hypothyroidism (11% to 14%)<span class="lexi-table-link-container"> (<a aria-label="Hypothyroidism table link" class="lexi-table-link" data-table-id="lexi-content-hypothyroidism" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-hypothyroidism')">table 4</a>)</span><span class="table-link" style="display:none;">Hypothyroidism</span>, increased serum albumin (21%), weight loss (7% to 13%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Hyperthyroidism" frame="border" id="lexi-content-hyperthyroidism" rules="all">
<caption style="text-align:center;">
<b>Nivolumab: Adverse Reaction: Hyperthyroidism</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Nivolumab)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Ipilimumab)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Nivolumab)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Ipilimumab)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">11%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">240 mg over 30 minutes every 2 weeks</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adjuvant treatment of urothelial carcinoma</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">351</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">348</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3 mg/kg over 60 minutes every 2 weeks</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Previously untreated metastatic melanoma</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">313</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">311</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Hypothyroidism" frame="border" id="lexi-content-hypothyroidism" rules="all">
<caption style="text-align:center;">
<b>Nivolumab: Adverse Reaction: Hypothyroidism</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Nivolumab)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Ipilimumab)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Nivolumab)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Ipilimumab)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">11%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">240 mg IV infused over 30 minutes once every 2 weeks x 16 weeks; followed by 480 mg infused over 30 minutes every 4 weeks beginning on week 17</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adjunctive treatment of resected esophageal or gastroesophageal junction cancer</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">532</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">260</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">14%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">480 mg IV over 30 min once every 4 weeks</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adjuvant treatment of melanoma</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">524</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">264</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">12%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3 mg/kg over 60 minutes every 2 weeks</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adjuvant treatment of melanoma</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">452</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">453</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">11%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">240 mg over 30 minutes every 2 weeks</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adjuvant treatment of urothelial carcinoma</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">351</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">348</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">11%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3 mg/kg over 60 minutes every 2 weeks</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Previously untreated metastatic melanoma</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">313</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">311</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (17% to 21%)<span class="lexi-table-link-container"> (<a aria-label="Abdominal Pain table link" class="lexi-table-link" data-table-id="lexi-content-abdominal-pain" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-abdominal-pain')">table 5</a>)</span><span class="table-link" style="display:none;">Abdominal Pain</span>, decreased appetite (13% to 22%), diarrhea (23% to 37%; grades 3/4: ≤5%)<span class="lexi-table-link-container"> (<a aria-label="Diarrhea table link" class="lexi-table-link" data-table-id="lexi-content-diarrhea" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-diarrhea')">table 6</a>)</span><span class="table-link" style="display:none;">Diarrhea</span>, increased serum amylase (17% to 34%), increased serum lipase (22% to 33%), nausea (14% to 30%; grades 3/4: &lt;1%), vomiting (20%; grades 3/4: ≤1%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Abdominal Pain" frame="border" id="lexi-content-abdominal-pain" rules="all">
<caption style="text-align:center;">
<b>Nivolumab: Adverse Reaction: Abdominal Pain</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Nivolumab)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Ipilimumab)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Nivolumab)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Ipilimumab)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">17%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">20%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">240 mg IV infused over 30 minutes once every 2 weeks x 16 weeks; followed by 480 mg infused over 30 minutes every 4 weeks beginning on week 17</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adjunctive treatment of resected esophageal or gastroesophageal junction cancer</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">532</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">260</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">21%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">23%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3 mg/kg over 60 minutes every 2 weeks</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adjuvant treatment of melanoma</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">452</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">453</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Diarrhea" frame="border" id="lexi-content-diarrhea" rules="all">
<caption style="text-align:center;">
<b>Nivolumab: Adverse Reaction: Diarrhea</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Nivolumab)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Ipilimumab)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Nivolumab)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Ipilimumab)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">All grades: 29%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">29%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">240 mg IV infused over 30 minutes once every 2 weeks x 16 weeks; followed by 480 mg infused over 30 minutes every 4 weeks beginning on week 17</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adjunctive treatment of resected esophageal or gastroesophageal junction cancer</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">532</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">260</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Grades 3/4: 0.9%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0.8%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">240 mg IV infused over 30 minutes once every 2 weeks x 16 weeks; followed by 480 mg infused over 30 minutes every 4 weeks beginning on week 17</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adjunctive treatment of resected esophageal or gastroesophageal junction cancer</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">532</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">260</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">All grades: 37%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">55%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3 mg/kg over 60 minutes every 2 weeks</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adjuvant treatment of melanoma</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">452</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">453</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">All grades: 23%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">16%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">480 mg IV over 30 min once every 4 weeks</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adjuvant treatment of melanoma</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">524</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">264</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Grades 3/4: 2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">11%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3 mg/kg over 60 minutes every 2 weeks</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adjuvant treatment of melanoma</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">452</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">453</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Grades 3/4: 1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">480 mg IV over 30 min once every 4 weeks</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adjuvant treatment of melanoma</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">524</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">264</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">All grades: 30%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">27%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">240 mg over 30 minutes every 2 weeks</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adjuvant treatment of urothelial carcinoma</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">351</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">348</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Grades 3/4: 3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">240 mg over 30 minutes every 2 weeks</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adjuvant treatment of urothelial carcinoma</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">351</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">348</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">All grades: 36%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">47%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3 mg/kg over 60 minutes every 2 weeks</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Previously untreated metastatic melanoma</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">313</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">311</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Grades 3/4: 5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3 mg/kg over 60 minutes every 2 weeks</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Previously untreated metastatic melanoma</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">313</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">311</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia (19% to 41%; grades 3/4: ≤3%)<span class="lexi-table-link-container"> (<a aria-label="Anemia table link" class="lexi-table-link" data-table-id="lexi-content-anemia" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-anemia')">table 7</a>)</span><span class="table-link" style="display:none;">Anemia</span>, leukopenia (14%), lymphocytopenia (27% to 44%; grades 3/4: ≤17%), neutropenia (10% to 24%; grades 3/4: ≤2%)<span class="lexi-table-link-container"> (<a aria-label="Neutropenia table link" class="lexi-table-link" data-table-id="lexi-content-neutropenia" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-neutropenia')">table 8</a>)</span><span class="table-link" style="display:none;">Neutropenia</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Anemia" frame="border" id="lexi-content-anemia" rules="all">
<caption style="text-align:center;">
<b>Nivolumab: Adverse Reaction: Anemia</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Nivolumab)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Ipilimumab)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Nivolumab)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Ipilimumab)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">All grades: 27%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">21%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">240 mg IV infused over 30 minutes once every 2 weeks x 16 weeks; followed by 480 mg infused over 30 minutes every 4 weeks beginning on week 17</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adjunctive treatment of resected esophageal or gastroesophageal junction cancer</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">532</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">260</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Grades 3/4: 0.8%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0.4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">240 mg IV infused over 30 minutes once every 2 weeks x 16 weeks; followed by 480 mg infused over 30 minutes every 4 weeks beginning on week 17</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adjunctive treatment of resected esophageal or gastroesophageal junction cancer</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">532</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">260</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">All grades: 26%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">34%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3 mg/kg over 60 minutes every 2 weeks</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adjuvant treatment of melanoma</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">452</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">453</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">All grades: 19%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">14%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">480 mg IV over 30 min once every 4 weeks</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adjuvant treatment of melanoma</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">524</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">264</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Grades 3/4: 0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0.5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3 mg/kg over 60 minutes every 2 weeks</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adjuvant treatment of melanoma</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">452</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">453</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">All grades: 30%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">28%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">240 mg over 30 minutes every 2 weeks</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adjuvant treatment of urothelial carcinoma</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">351</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">348</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Grades 3/4: 1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0.9%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">240 mg over 30 minutes every 2 weeks</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adjuvant treatment of urothelial carcinoma</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">351</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">348</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">All grades: 41%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">41%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3 mg/kg over 60 minutes every 2 weeks</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Previously untreated metastatic melanoma</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">313</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">311</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Grades 3/4: 3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3 mg/kg over 60 minutes every 2 weeks</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Previously untreated metastatic melanoma</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">313</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">311</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Neutropenia" frame="border" id="lexi-content-neutropenia" rules="all">
<caption style="text-align:center;">
<b>Nivolumab: Adverse Reaction: Neutropenia</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Nivolumab)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Ipilimumab)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Nivolumab)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Ipilimumab)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">All grades: 24%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">23%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">240 mg IV infused over 30 minutes once every 2 weeks x 16 weeks; followed by 480 mg infused over 30 minutes every 4 weeks beginning on week 17</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adjunctive treatment of resected esophageal or gastroesophageal junction cancer</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">532</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">260</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Grades 3/4: 2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0.4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">240 mg IV infused over 30 minutes once every 2 weeks x 16 weeks; followed by 480 mg infused over 30 minutes every 4 weeks beginning on week 17</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adjunctive treatment of resected esophageal or gastroesophageal junction cancer</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">532</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">260</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">All grades: 13%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3 mg/kg over 60 minutes every 2 weeks</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adjuvant treatment of melanoma</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">452</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">453</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">All grades: 10%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">10%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">480 mg IV over 30 min once every 4 weeks</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adjuvant treatment of melanoma</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">524</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">264</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Grades 3/4: 0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0.5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3 mg/kg over 60 minutes every 2 weeks</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adjuvant treatment of melanoma</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">452</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">453</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Grades 3/4: 0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0.4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">480 mg IV over 30 min once every 4 weeks</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adjuvant treatment of melanoma</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">524</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">264</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">All grades: 11%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">10%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">240 mg over 30 minutes every 2 weeks</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adjuvant treatment of urothelial carcinoma</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">351</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">348</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Grades 3/4: 0.6%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0.3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">240 mg over 30 minutes every 2 weeks</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adjuvant treatment of urothelial carcinoma</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">351</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">348</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatitis (2% to 11%), increased serum alanine aminotransferase (20% to 25%)<span class="lexi-table-link-container"> (<a aria-label="Increased Serum Alanine Aminotransferase table link" class="lexi-table-link" data-table-id="lexi-content-increased-serum-alanine-aminotransferase" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-increased-serum-alanine-aminotransferase')">table 9</a>)</span><span class="table-link" style="display:none;">Increased Serum Alanine Aminotransferase</span>, increased serum alkaline phosphatase (21% to 27%), increased serum aspartate aminotransferase (24% to 29%)<span class="lexi-table-link-container"> (<a aria-label="Increased Serum Aspartate Aminotransferase table link" class="lexi-table-link" data-table-id="lexi-content-increased-serum-aspartate-aminotransferase" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-increased-serum-aspartate-aminotransferase')">table 10</a>)</span><span class="table-link" style="display:none;">Increased Serum Aspartate Aminotransferase</span>, increased serum bilirubin (13%)<span class="lexi-table-link-container"> (<a aria-label="Increased Serum Bilirubin table link" class="lexi-table-link" data-table-id="lexi-content-increased-serum-bilirubin" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-increased-serum-bilirubin')">table 11</a>)</span><span class="table-link" style="display:none;">Increased Serum Bilirubin</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Increased Serum Alanine Aminotransferase" frame="border" id="lexi-content-increased-serum-alanine-aminotransferase" rules="all">
<caption style="text-align:center;">
<b>Nivolumab: Adverse Reaction: Increased Serum Alanine Aminotransferase</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Nivolumab)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comparator</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Nivolumab)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Comparator)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">20%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">16%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">240 mg IV infused over 30 minutes once every 2 weeks x 16 weeks; followed by 480 mg infused over 30 minutes every 4 weeks beginning on week 17</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adjunctive treatment of resected esophageal or gastroesophageal junction cancer</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">532</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">260</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">25%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Ipilimumab: 40%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3 mg/kg over 60 minutes every 2 weeks</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adjuvant treatment of melanoma</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">452</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">453</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">20%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">15%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">480 mg IV over 30 min once every 4 weeks</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adjuvant treatment of melanoma</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">524</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">264</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">23%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">15%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">240 mg over 30 minutes every 2 weeks</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adjuvant treatment of urothelial carcinoma</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">351</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">348</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">25%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Ipilimumab: 29%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3 mg/kg over 60 minutes every 2 weeks</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Previously untreated metastatic melanoma</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">313</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">311</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">25%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Dacarbazine: 19%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3 mg/kg over 60 minutes every 2 weeks</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Previously untreated metastatic melanoma</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">206</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">205</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Increased Serum Aspartate Aminotransferase" frame="border" id="lexi-content-increased-serum-aspartate-aminotransferase" rules="all">
<caption style="text-align:center;">
<b>Nivolumab: Adverse Reaction: Increased Serum Aspartate Aminotransferase</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Nivolumab)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comparator</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Nivolumab)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Comparator)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">27%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">22%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">240 mg IV infused over 30 minutes once every 2 weeks x 16 weeks; followed by 480 mg infused over 30 minutes every 4 weeks beginning on week 17</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adjunctive treatment of resected esophageal or gastroesophageal junction cancer</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">532</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">260</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">25%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">16%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">480 mg IV over 30 min once every 4 weeks</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adjuvant treatment of melanoma</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">524</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">264</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">24%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Ipilimumab: 33%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3 mg/kg over 60 minutes every 2 weeks</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adjuvant treatment of melanoma</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">452</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">453</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">24%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">16%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">240 mg over 30 minutes every 2 weeks</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adjuvant treatment of urothelial carcinoma</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">351</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">348</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">29%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Ipilimumab: 29%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3 mg/kg over 60 minutes every 2 weeks</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Previously untreated metastatic melanoma</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">313</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">311</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">24%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Dacarbazine: 19%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3 mg/kg over 60 minutes every 2 weeks</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Previously untreated metastatic melanoma</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">206</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">205</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Increased Serum Bilirubin" frame="border" id="lexi-content-increased-serum-bilirubin" rules="all">
<caption style="text-align:center;">
<b>Nivolumab: Adverse Reaction: Increased Serum Bilirubin</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Nivolumab)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Dacarbazine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Nivolumab)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Dacarbazine)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">13%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3 mg/kg over 60 minutes every 2 weeks</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Previously untreated metastatic melanoma</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">206</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">205</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Antibody development (11%; neutralizing: &lt;1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Asthenia (≤59%), dizziness (11%), fatigue (≤59%), headache (23%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (10% to 21%), musculoskeletal pain (21% to 42%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Increased serum creatinine (12% to 19%)<span class="lexi-table-link-container"> (<a aria-label="Increased Serum Creatinine table link" class="lexi-table-link" data-table-id="lexi-content-increased-serum-creatinine" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-increased-serum-creatinine')">table 12</a>)</span><span class="table-link" style="display:none;">Increased Serum Creatinine</span>, kidney impairment (≤17%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Increased Serum Creatinine" frame="border" id="lexi-content-increased-serum-creatinine" rules="all">
<caption style="text-align:center;">
<b>Nivolumab: Adverse Reaction: Increased Serum Creatinine</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Nivolumab)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Ipilimumab)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Nivolumab)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Ipilimumab)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">15%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">13%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">480 mg IV over 30 min once every 4 weeks</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adjuvant treatment of melanoma</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">524</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">264</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">12%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">13%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3 mg/kg over 60 minutes every 2 weeks</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adjuvant treatment of melanoma</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">452</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">453</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">19%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">17%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3 mg/kg over 60 minutes every 2 weeks</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Previously untreated metastatic melanoma</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">313</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">311</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough (≤28%), dyspnea (≤18%), dyspnea on exertion (≤18%), productive cough (≤28%), upper respiratory tract infection (17% to 22%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (16%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Erythema of skin (10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Adrenocortical insufficiency (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Colitis (≤6%; severe: 2%), constipation (10%), intestinal perforation (&lt;10%), stomatitis (&lt;10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased gamma-glutamyl transferase (grades 3/4: 4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Infusion-related reaction (≤6%; severe: &lt;1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Sjögren disease (&lt;10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Neuritis (&lt;10%), peripheral nerve palsy (peroneal: &lt;10%), peripheral neuropathy (&lt;10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Myopathy (&lt;10%), myositis (&lt;10%), polymyositis (&lt;10%), rheumatism (spondyloarthropathy: &lt;10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Nephritis (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Pneumonitis (3%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Myocarditis, vasculitis (including acral ischemia [Suenaga 2021])</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Diabetic ketoacidosis, hypoparathyroidism, hypophysitis, thyroiditis, type I diabetes mellitus</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Duodenitis, gastritis, pancreatitis</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Aplastic anemia, hemolytic anemia, immune thrombocytopenia, lymphadenitis (histiocytic necrotizing lymphadenitis [Kikuchi lymphadenitis])</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Organ transplant rejection (solid), sarcoidosis</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Systemic inflammatory response syndrome</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Demyelinating disease, encephalitis (including limbic), exacerbation of myasthenia gravis, Guillain-Barré syndrome, meningitis, myasthenia (myasthenic syndrome), neuropathy (autoimmune), paresis (nerve)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthritis, myelitis, polymyalgia rheumatica, rhabdomyolysis</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Iritis, uveitis</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Acute coronary syndrome (Cancela-Diez 2020), heart failure (Samejimi 2020), pericardial effusion (Sawada 2021), pericarditis (de Almeida 2018)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Bullous pemphigoid (Panariello 2018), lichen planus (Martos-Cabrera 2023), nail disease (including nail discoloration [bluish-gray] and onycholysis) (Ocampo 2021, Zahoor 2022), skin photosensitivity (Navarro-Trivino 2022), Stevens-Johnson syndrome (Dasanu 2019), toxic epidermal necrolysis (Basu 2020)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Graves disease (Yamada 2020)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Cholangitis (SITC [Brahmer 2021]), cholecystitis (SITC [Brahmer 2021]), esophagitis (SITC [Brahmer 2021]), exacerbation of ulcerative colitis (Iwamoto 2020), ileitis (Dasanu 2020), oral mucosa ulcer (lip) (Sato 2021), sclerosing cholangitis (Hirasawa 2021), xerostomia (SITC [Brahmer 2021])</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Acquired blood coagulation disorder (hemophilia) (Gokozan 2019), autoimmune hemolytic anemia (Palla 2016; Shaikh 2018), disseminated intravascular coagulation (Tanios 2019), hemophagocytic lymphohistiocytosis (Hantel 2018), pancytopenia (Uehara 2020), pure red cell aplasia (SITC [Brahmer 2021]), T-cell lymphoma (peripheral, after long term therapy) (Koda 2021), thrombotic thrombocytopenic purpura (Gergi 2020), tumor lysis syndrome (Sugimoto 2020)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Cytokine release syndrome (Oda 2019), drug reaction with eosinophilia and systemic symptoms (Ai 2021, Lu 2019)</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Dermatomyositis (Messer 2020), graft-versus-host disease (treatment refractory, severe acute and chronic) (Amerikanou 2021)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Aseptic meningitis (Cordes 2019), cerebral hemorrhage (Hasegawa 2019), myasthenia gravis (Mehta 2017), reversible posterior leukoencephalopathy syndrome (Hussein 2017)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Costochondritis (Kuba 2020), discoid lupus erythematous (Manjunath 2022), inflammatory polyarthropathy (Abe 2022), Lambert-Eaton syndrome (Gill 2021), myalgia (SITC [Brahmer 2021]), subacute cutaneous lupus erythematosus (Zitouni 2019)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blepharoptosis (Campredon 2018), dry eye syndrome (SITC [Brahmer 2021]), keratitis (Baughman 2017)</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Hearing loss (bilateral sensorineural hearing loss [BSHL]) (Tampio 2021)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Acute kidney injury (SITC [Brahmer 2021], Cortazar 2016), acute renal tubular disease (Yang 2023), membranous glomerulonephritis (Wakabayashi 2022)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Pleural effusion (Sawada 2021)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Granuloma (annulare) (Fawaz 2021), inflammation (periaortitis) (Hotta 2020), Vogt-Koyanagi-Harada disease (Arai 2017)</p></div>
<div class="block coi drugH1Div" id="F26702130"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">There are no contraindications listed in the manufacturer's US labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Hypersensitivity to nivolumab or any component of the formulation.</p></div>
<div class="block war drugH1Div" id="F26821961"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Adverse reactions (immune mediated): PD-1/PD-L1 blockers (including nivolumab) remove immune response inhibition, thus potentially breaking peripheral tolerance and inducing immune-mediated adverse reactions. Severe and fatal immune-mediated adverse reactions may occur in any organ system or tissue. Reactions generally occur during treatment (may occur at any time after nivolumab initiation); reactions may also occur after nivolumab discontinuation. Early identification and management of immune-mediated adverse reactions are necessary to ensure safe use of nivolumab. If suspected immune-mediated reactions occur, initiate appropriate workup to exclude alternative causes (including infection). Medically manage immune-mediated adverse reactions promptly and refer for specialty consultation as appropriate. See "Dosing for Toxicity" for specific instructions.</p>
<p style="text-indent:-2em;margin-left:4em;">• Infusion-related reactions: Infusion-related reactions have occurred with both single-agent nivolumab and when used in combination with ipilimumab; severe reactions, although rare, were observed.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns: </i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Autoimmune disorders: Anti-PD-1 monoclonal antibodies generate an immune response that may aggravate underlying autoimmune disorders or prior immune-related adverse events. A retrospective study analyzed the safety and efficacy of treatment with anti-PD-1 monoclonal antibodies (eg, nivolumab or pembrolizumab) in patients with melanoma with preexisting autoimmune disease or prior significant ipilimumab-mediated adverse immune events. Results showed that while immune toxicities associated with this class of therapy did occur, most reactions were mild and easily manageable, and did not require permanent drug therapy discontinuation. A significant percentage of patients achieved clinical response with anti-PD-1 monoclonal antibody therapy, despite baseline autoimmunity or prior ipilimumab-related adverse events (Menzies 2017).</p>
<p style="text-indent:-2em;margin-left:4em;">• Hematopoietic cell transplant: Fatal and other serious complications may occur in patients who receive allogeneic hematopoietic cell transplant (HCT) before or after treatment with an anti-PD-L1/PD-1 monoclonal antibody. Transplant-related complications included hyperacute graft-versus-host disease (GVHD), acute or chronic GVHD, hepatic veno-occlusive disease (also known as sinusoidal obstruction syndrome) after reduced-intensity conditioning, and steroid-requiring febrile syndrome (with no identified infectious etiology). These complications may occur despite intervening therapy between PD-L1/PD-1 blockade and HCT. Manage early signs/symptoms of transplant-related complications promptly. Assess the risks/benefits of treatment with an anti-PD-L1/PD-1 monoclonal antibody prior to or after an allogenic HCT.</p>
<p style="text-indent:-2em;margin-left:4em;">• Multiple myeloma: An increase in mortality was noted in randomized studies of patients with multiple myeloma who received the addition of a PD-1 blocking agent (including nivolumab) to a thalidomide analogue plus dexamethasone. Nivolumab should not be used to treat multiple myeloma unless part of a clinical trial.</p>
<p style="text-indent:-2em;margin-left:4em;">• Myasthenia gravis: Checkpoint inhibitors may worsen or precipitate new myasthenia gravis (MG), especially within the first 16 weeks of treatment; use with caution. Patients with well-controlled MG may be considered for checkpoint inhibitor therapy if MG treatment is maintained (or reinitiated in patients whose MG is in remission), combination therapy (eg, anti–CTLA-4 with anti–PD-a/PD-L1 monoclonal antibodies) is avoided, and respiratory and bulbar function are closely followed. In patients who develop overt MG during checkpoint inhibitor therapy, early aggressive treatment with plasma exchange or IVIG in combination with high-dose corticosteroids may be required (AAN [Narayanaswami 2021]).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Special populations: </b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: In patients with metastatic (unresectable) non–small cell lung cancer who received nivolumab/ipilimumab or nivolumab/ipilimumab with platinum-based doublet chemotherapy, patients ≥75 years of age experienced a higher discontinuation rate due to adverse reactions, compared to younger patients. In the malignant pleural mesothelioma study of nivolumab in combination with ipilimumab, patients ≥75 years of age experienced a higher rate of serious adverse reactions and discontinuation due to adverse reactions.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Select patients for first-line nivolumab/ipilimumab treatment of metastatic NSCLC based on PD-L1 expression. Information on tests to detect PD-L1 expression may be found at <a href="/external-redirect?target_url=http%3A%2F%2Fwww.fda.gov%2Fcompaniondiagnostics&amp;token=SHauxSdf9qNc6lLK16E8IFPiEHUnQ%2FrX%2FFBRnAtp%2BYOOMBGgh36vrA79ff4L%2FMZW&amp;TOPIC_ID=115765" target="_blank">http://www.fda.gov/companiondiagnostics</a>.</p></div>
<div class="block foc drugH1Div" id="F26819876"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Opdivo: 40 mg/4 mL (4 mL); 100 mg/10 mL (10 mL); 120 mg/12 mL (12 mL); 240 mg/24 mL (24 mL) [contains polysorbate 80]</p></div>
<div class="block geq drugH1Div" id="F26819874"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F26844488"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Opdivo Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mg/4 mL (per mL): $374.25</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg/10 mL (per mL): $374.25</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">120MG/12ML (per mL): $374.25</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">240MG/24ML (per mL): $374.25</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52871870"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Opdivo: 40 mg/4 mL (4 mL); 100 mg/10 mL (10 mL) [contains polysorbate 80]</p></div>
<div class="block admp drugH1Div" id="F52614578"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Nivolumab and nivolumab/relatlimab are different products and are <b>not</b> interchangeable; verify labels to ensure appropriate medication.</p>
<p style="text-indent:-2em;margin-left:2em;">IV: Administer as an IV infusion over 30 minutes through a line with a sterile, nonpyrogenic, low protein binding 0.2 to 1.2 micrometer in-line filter. If administering as part of a combination regimen, use separate infusion bags and filters for each infusion. Do not administer other medications through the same IV line. Flush IV line at the end of the infusion. If mild or moderate infusion reaction occurs, interrupt infusion or slow infusion rate; if infusion reaction is severe or life-threatening, discontinue nivolumab.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Combination therapy with ipilimumab:</i> When administered in combination with ipilimumab, infuse nivolumab first followed by ipilimumab on the same day.</p></div>
<div class="block adm drugH1Div" id="F26827913"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b> Administer as an IV infusion over 30 minutes. Refer to protocol for infusion rates in off-label dosing. Infuse through a line with a sterile, nonpyrogenic, low protein binding 0.2 to 1.2 micrometer in-line filter. If administering as part of a combination regimen, use separate infusion bags and filters for each infusion. Do not administer other medications through the same IV line. Flush IV line at the end of the infusion.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Combination therapy with ipilimumab:</i> When administered in combination with ipilimumab, administer nivolumab first followed by ipilimumab on the same day.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Combination therapy with ipilimumab and platinum-based doublet chemotherapy:</i> When administered in combination with ipilimumab and platinum-based doublet chemotherapy, infuse nivolumab first, followed by ipilimumab, and then the platinum-based doublet chemotherapy (all on the same day).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Combination therapy with platinum-based doublet chemotherapy:</i> When administered in combination with platinum-based doublet chemotherapy, infuse nivolumab first, followed by the platinum-based doublet chemotherapy (on the same day).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Combination therapy with fluoropyrimidine- and platinum-containing chemotherapy:</i> When administered in combination with fluoropyrimidine- and platinum-containing chemotherapy, infuse nivolumab first, followed by the fluoropyrimidine- and platinum-containing chemotherapy (on the same day).</p>
<p style="text-indent:-2em;margin-left:2em;">Check label to ensure appropriate product is being administered; nivolumab and nivolumab/relatlimab are different products and are <b>NOT</b> interchangeable.</p></div>
<div class="block sts drugH1Div" id="F26822038"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store intact vials at 2°C to 8°C (36°F to 46°F); do not freeze. Protect from light. Do not shake. After preparation in NS or D5W, store the diluted infusion solution at room temperature and room light for no more than 8 hours (including infusion time) or refrigerated (protected from light) at 2°C to 8°C (36°F to 46°F) for no more than 7 days (including infusion time). Infusion must be completed within 8 hours of preparation (if stored at room temperature) or 7 days of preparation (if refrigerated). Do not freeze solutions prepared for infusion.</p></div>
<div class="block meg drugH1Div" id="F27369132"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and at <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2023%2F125554s119lbl.pdf%23page%3D135&amp;token=hxlOKQPsZd9oIVfZ8%2FStXDLDMpP4vXawfzXzDUqvR5L3dL4%2FiyeQtEO8EIP4tO%2Fau5M1DLH2fZonvELKsPB%2FpL%2BNKKPm8gXd1mIhEB1AYUIGenk3gyXoGKpTixvFECvb&amp;TOPIC_ID=115765" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125554s119lbl.pdf#page=135</a>, must be dispensed with this medication.</p></div>
<div class="block usep drugH1Div" id="F53571193"><span class="drugH1">Use</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>Indications</i>
<i> including pediatric patients:</i></p>
<p style="text-indent:-2em;margin-left:4em;">Treatment of microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (CRC) that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan, single agent or in combination with ipilimumab; treatment of unresectable or metastatic melanoma, single agent or in combination with ipilimumab; adjuvant treatment of melanoma with involvement of lymph nodes or metastatic disease in patients who have undergone complete resection (FDA approved in ages ≥12 years and adults). <b>Note:</b> FDA approval for MSI-H or dMMR metastatic CRC is through an accelerated process; continued approval is dependent upon verification of clinical benefit in further trials.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Indications approved only in adults:</i></p>
<p style="text-indent:-2em;margin-left:4em;">Treatment of recurrent or metastatic squamous cell carcinoma of the head and neck in patients with disease progression on or after platinum-based therapy; treatment (in combination with ipilimumab) of hepatocellular carcinoma (HCC) in patients who have been previously treated with sorafenib; treatment of classical Hodgkin lymphoma (cHL) in patients who have relapsed or progressed following autologous hematopoietic stem cell transplant (HSCT) and brentuximab vedotin, or three or more lines of systemic therapy that includes autologous HSCT; adjuvant treatment of melanoma with involvement of lymph nodes or metastatic disease following complete resection; treatment of unresectable or metastatic melanoma (as a single agent or in combination with ipilimumab); treatment of metastatic non-small cell lung cancer (NSCLC) that has progressed on or after platinum-based chemotherapy (patients with EGFR or ALK genomic tumor aberrations should have disease progression [on approved EGFR- or ALK-directed therapy] prior to receiving nivolumab); neoadjuvant treatment (in combination with platinum-doublet chemotherapy) of resectable (tumors ≥4 cm or node positive) NSCLC; first-line treatment of metastatic NSCLC (in combination with ipilimumab) in patients whose tumors express PD-L1 (≥1%) as determined by an approved test, and with no EGFR or ALK genomic tumor aberrations; first-line treatment of metastatic or recurrent NSCLC (in combination with ipilimumab and 2 cycles of platinum doublet chemotherapy) in patients with no EGFR or ALK genomic tumor aberrations; treatment (as a single agent) of advanced renal cell carcinoma (RCC) in patients who have received prior antiangiogenic therapy; first-line treatment of advanced RCC (in combination with cabozantinib); treatment of intermediate or poor risk, advanced RCC (in combination with ipilimumab); treatment of locally advanced or metastatic urothelial carcinoma in patients with disease progression during or following a platinum-containing therapy or disease progression within 12 months of neoadjuvant or adjuvant treatment with a platinum-containing therapy; adjuvant treatment of urothelial carcinoma in patients who are at high-risk of recurrence after undergoing radical resection; adjuvant treatment of completely resected esophageal or gastroesophageal junction cancer in patients with residual pathologic disease who have received neoadjuvant chemoradiotherapy; treatment of advanced or metastatic esophageal adenocarcinoma (in combination with fluoropyrimidine- and platinum-containing chemotherapy); treatment of unresectable advanced, recurrent, or metastatic esophageal squamous cell carcinoma after prior fluoropyrimidine- and platinum-based chemotherapy; first-line treatment of unresectable malignant pleural mesothelioma (in combination with ipilimumab); treatment of advanced or metastatic gastric cancer and gastroesophageal junction cancer (in combination with fluoropyrimidine- and platinum-containing chemotherapy) (All indications: FDA approved in adults).</p></div>
<div class="block mst drugH1Div" id="F27560227"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Nivolumab may be confused with atezolizumab, avelumab, cemiplimab, dostarlimab, durvalumab, ipilimumab, naxitamab, necitumumab, nivolumab/relatlimab, pembrolizumab.</p>
<p style="text-indent:-2em;margin-left:4em;">Opdivo may be confused with Odomzo, Onivyde, Opdualag, Opfolda.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Other safety concerns:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Nivolumab (Opdivo) may be confused with nivolumab/relatlimab (Opdualag); these products are not interchangeable. Verify product prior to preparation and administration to prevent medication errors.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F26736581"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F26736578"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Acetaminophen: May diminish the therapeutic effect of Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antibiotics: May diminish the therapeutic effect of Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Corticosteroids (Systemic): May diminish the therapeutic effect of Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies). Management: Carefully consider the need for corticosteroids, at doses of a prednisone-equivalent of 10 mg or more per day, during the initiation of immune checkpoint inhibitor therapy. Use of corticosteroids to treat immune related adverse events is still recommended<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Desmopressin: Hyponatremia-Associated Agents may enhance the hyponatremic effect of Desmopressin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Efgartigimod Alfa: May diminish the therapeutic effect of Fc Receptor-Binding Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inhibitors of the Proton Pump (PPIs and PCABs): May diminish the therapeutic effect of Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ketoconazole (Systemic): Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies) may enhance the hepatotoxic effect of Ketoconazole (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rozanolixizumab: May diminish the therapeutic effect of Fc Receptor-Binding Agents.<i> Risk C: Monitor therapy</i></p></div>
<div class="block rep_considerations drugH1Div" id="F49308550"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Verify pregnancy status prior to treatment initiation in patients who could become pregnant. Patients who could become pregnant should use highly effective contraception during therapy and for 5 months after nivolumab treatment has been discontinued.</p></div>
<div class="block pri drugH1Div" id="F26821958"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Based on information from animal reproduction studies and the mechanism of action, in utero exposure to nivolumab may cause fetal harm. Nivolumab is a humanized monoclonal antibody (IgG<sub>4</sub>). Potential placental transfer of human IgG is dependent upon the IgG subclass and gestational age, generally increasing as pregnancy progresses. The lowest exposure would be expected during the period of organogenesis (Palmeira 2012; Pentsuk 2009).</p></div>
<div class="block mopp drugH1Div" id="F53571192"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Hepatic and renal function tests (baseline and periodic), thyroid function (baseline and periodically [eg, at treatment day 1 and every 6 weeks]); blood glucose. Monitor for signs/symptoms of adrenal insufficiency, hypophysitis, thyroid disorders, immune-mediated colitis, pneumonitis, rash/dermatologic toxicity, encephalitis (changes in neurologic function); monitor for infusion reactions. Verify pregnancy status prior to treatment initiation (in patients who could become pregnant). In adult patients, additional cancer-specific monitoring parameters may be necessary (refer to specific protocols or manufacturer labeling).</p></div>
<div class="block pha drugH1Div" id="F26822041"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:-2em;margin-left:2em;">Nivolumab is a fully human immunoglobulin G4 (IgG4) monoclonal antibody that selectively inhibits programmed cell death-1 (PD-1) activity by binding to the PD-1 receptor to block the ligands PD-L1 and PD-L2 from binding. The negative PD-1 receptor signaling that regulates T-cell activation and proliferation is therefore disrupted (Robert 2015). This releases PD-1 pathway-mediated inhibition of the immune response, including the antitumor immune response.</p>
<p style="text-indent:-2em;margin-left:2em;">Combining nivolumab (anti-PD-1) with ipilimumab (anti-CTLA-4) results in enhanced T-cell function that is greater than that of either antibody alone, resulting in improved anti-tumor responses in metastatic melanoma and advanced renal cell carcinoma.</p></div>
<div class="block phk drugH1Div" id="F26822043"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>dss</sub>: 6.8 L; the predicted exposure after a 30-minute infusion is comparable to that seen with a 60-minute infusion.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: ~25 days.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Clearance (geometric mean at steady state): 8.2 mL/hour; compared to nivolumab monotherapy, nivolumab clearance is increased 29% when 1 mg/kg nivolumab is administered every 3 weeks in combination with 3 mg/kg ipilimumab.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F26732989"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Opdivo</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Opdivo</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Nivolumab bms | Opdivo</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Opdivo</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Opdivo</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Opdivo</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Opdivo</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Nivolumab bms | Opdivo</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Opdivo</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Opdivo</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Opdivo</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Nivolumab bms | Opdivo</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Nivolumab bms | Opdivo</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Opdivo</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Opdivo</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Opdivo</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Opdivo</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Opdivo</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Nivolumab bms | Opdivo</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Opdivo</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Opdivo</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Opdivo</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Opdivo</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Opdivo</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Opdyta</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Opdivo</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Opdivo</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Opdivo</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Opdivo</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Opdivo</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Opdivo</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Opdivo</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Opdivo</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Opdivo</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Opdivo</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Opdivo</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Opdivo</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Opdivo</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Opdivo</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Opdivo</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Opdivo</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Opdivo</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Opdivo</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Opdivo</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Opdivo</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Opdivo</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Opdivo</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Opdivo</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Opdivo</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Opdivo</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Opdivo</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Opdivo</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Opdivo</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-35029182">
<a name="35029182"></a>Abe K, Ishikawa Y, Fujiwara M, et al. Immune checkpoint inhibitor-induced refractory polyarthritis rapidly improved by sarilumab and monitoring with joint ultrasonography: A case report. <i>Medicine (Baltimore)</i>. 2022;101(2):e28428. doi:10.1097/MD.0000000000028428<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/35029182/pubmed" id="35029182" target="_blank">35029182</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34599025">
<a name="34599025"></a>Ai L, Gao J, Zhao S, et al. Nivolumab-associated DRESS in a genetic susceptible individual. <i>J Immunother Cancer</i>. 2021;9(10):e002879. doi:10.1136/jitc-2021-002879<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/34599025/pubmed" id="34599025" target="_blank">34599025</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3960626">
<a name="3960626"></a>Alade SL, Brown RE, Paquet A Jr. Polysorbate 80 and E-Ferol toxicity. <i>Pediatrics</i>. 1986;77(4):593-597.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/3960626/pubmed" id="3960626" target="_blank">3960626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28476244">
<a name="28476244"></a>Alessandrino F, Tirumani SH, Krajewski KM, et al. Imaging of hepatic toxicity of systemic therapy in a tertiary cancer centre: chemotherapy, haematopoietic stem cell transplantation, molecular targeted therapies, and immune checkpoint inhibitors. <i>Clin Radiol</i>. 2017;72(7):521-533. doi:10.1016/j.crad.2017.04.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/28476244/pubmed" id="28476244" target="_blank">28476244</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34715051">
<a name="34715051"></a>Amerikanou R, Neill L, Shafat M, et al. Multi-organ graft-versus-host disease after nivolumab for relapsed Hodgkin lymphoma: the role of plasma exchange. <i>Lancet Haematol</i>. 2021;8(11):e862. doi:10.1016/S2352-3026(21)00202-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/34715051/pubmed" id="34715051" target="_blank">34715051</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30009063">
<a name="30009063"></a>Ansari J, Ali M, Farrag A, Ali AM, Alhamad A. Efficacy of nivolumab in a patient with metastatic renal cell carcinoma and end-stage renal disease on dialysis: case report and literature review. <i>Case Reports Immunol</i>. 2018;2018:1623957. doi:10.1155/2018/1623957<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/30009063/pubmed" id="30009063" target="_blank">30009063</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25482239">
<a name="25482239"></a>Ansell SM, Lesokhin AM, Borrello I, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. <i>N Engl J Med</i>. 2015;372(4):311-319.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/25482239/pubmed" id="25482239" target="_blank">25482239</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27649838">
<a name="27649838"></a>Arai T, Harada K, Usui Y, Irisawa R, Tsuboi R. Case of acute anterior uveitis and Vogt-Koyanagi-Harada syndrome-like eruptions induced by nivolumab in a melanoma patient. <i>J Dermatol</i>. 2017;44(8):975-976. doi:10.1111/1346-8138.13612<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/27649838/pubmed" id="27649838" target="_blank">27649838</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27918725">
<a name="27918725"></a>Armenian SH, Lacchetti C, Barac A, et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. <i>J Clin Oncol.</i> 2017;35(8):893-911. doi:10.1200/JCO.2016.70.5400<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/27918725/pubmed" id="27918725" target="_blank">27918725</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32961119">
<a name="32961119"></a>Ascierto PA, Del Vecchio M, Mandalá M, et al. Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial. <i>Lancet Oncol</i>. 2020;21(11):1465-1477. doi:10.1016/S1470-2045(20)30494-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/32961119/pubmed" id="32961119" target="_blank">32961119</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Atkins.1">
<a name="Atkins.1"></a>Atkins MB. Overview of the treatment of renal cell carcinoma. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 23, 2022a.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35442713">
<a name="35442713"></a>Atkins MB, Jegede OA, Haas NB, et al. Phase II study of nivolumab and salvage nivolumab/ipilimumab in treatment-naive patients with advanced clear cell renal cell carcinoma (HCRN GU16-260-Cohort A). <i>J Clin Oncol</i>. 2022b;40(25):2913-2923. doi:10.1200/JCO.21.02938<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/35442713/pubmed" id="35442713" target="_blank">35442713</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33485464">
<a name="33485464"></a>Baas P, Scherpereel A, Nowak A, et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. <i>Lancet.</i> 2021;397(10272):375-386. doi:10.1016/S0140-6736(20)32714-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/33485464/pubmed" id="33485464" target="_blank">33485464</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28019091">
<a name="28019091"></a>Bajaj G, Wang X, Agrawal S, Gupta M, Roy A, Feng Y. Model-based population pharmacokinetic analysis of nivolumab in patients with solid tumors. <i>CPT</i>
<i>Pharmacometrics Syst Pharmacol</i>. 2017;6(1):58-66. doi:10.1002/psp4.12143<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/28019091/pubmed" id="28019091" target="_blank">28019091</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34077643">
<a name="34077643"></a>Bajorin DF, Witjes JA, Gschwend JE, et al. Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma. <i>N Engl J Med</i>. 2021;384(22):2102-2114. doi:10.1056/NEJMoa2034442<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/34077643/pubmed" id="34077643" target="_blank">34077643</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28973656">
<a name="28973656"></a>Barroso-Sousa R, Barry WT, Garrido-Castro AC, et al. Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis. <i>JAMA Oncol</i>. 2018;4(2):173-182. doi:10.1001/jamaoncol.2017.3064<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/28973656/pubmed" id="28973656" target="_blank">28973656</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32281097">
<a name="32281097"></a>Basu P, Tong Y, Hinds BR, Schneider JA. Nivolumab-induced toxic epidermal necrolysis with retiform purpura. <i>Br J Dermatol</i>. 2020;183(2):e32. doi:10.1111/bjd.19031<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/32281097/pubmed" id="32281097" target="_blank">32281097</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28856338">
<a name="28856338"></a>Baughman DM, Lee CS, Snydsman BE, Jung HC. Bilateral uveitis and keratitis following nivolumab treatment for metastatic melanoma. <i>Med Case Rep (Wilmington)</i>. 2017;3(2):8. doi:10.21767/2471-8041.100044<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/28856338/pubmed" id="28856338" target="_blank">28856338</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26412456">
<a name="26412456"></a>Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. <i>N Engl J Med</i>. 2015;373(17):1627-1639.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/26412456/pubmed" id="26412456" target="_blank">26412456</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27141885">
<a name="27141885"></a>Boutros C, Tarhini A, Routier E, et al. Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. <i>Nat Rev Clin Oncol</i>. 2016;13(8):473-486. doi:10.1038/nrclinonc.2016.58<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/27141885/pubmed" id="27141885" target="_blank">27141885</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26028407">
<a name="26028407"></a>Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. <i>N Engl J Med</i>. 2015;373(2):123-135.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/26028407/pubmed" id="26028407" target="_blank">26028407</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34172516">
<a name="34172516"></a>Brahmer JR, Abu-Sbeih H, Ascierto PA, et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. <i>J Immunother Cancer</i>. 2021;9(6):e002435. doi:10.1136/jitc-2021-002435<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/34172516/pubmed" id="34172516" target="_blank">34172516</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29442540">
<a name="29442540"></a>Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline. <i>J Clin Oncol</i>. 2018;36(17):1714-1768. doi:10.1200/JCO.2017.77.6385<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/29442540/pubmed" id="29442540" target="_blank">29442540</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29594059">
<a name="29594059"></a>Campredon P, Imbert P, Mouly C, Grunenwald S, Mazières J, Caron P. Severe inflammatory ophthalmopathy in a euthyroid patient during nivolumab treatment. <i>Eur Thyroid J</i>. 2018;7(2):84-87. doi:10.1159/000485742<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/29594059/pubmed" id="29594059" target="_blank">29594059</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31382863">
<a name="31382863"></a>Cancela-Díez B, Gómez-De Rueda F, Antolinos Pérez MJ, Jiménez-Morales A, López-Hidalgo JL. Acute coronary syndrome and recurrent colitis as immune-related adverse events in a lung cancer patient. <i>J Oncol Pharm Pract</i>. 2020;26(1):252-255. doi:10.1177/1078155219865596<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/31382863/pubmed" id="31382863" target="_blank">31382863</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27311362">
<a name="27311362"></a>Carlo MI, Feldman DR. Response to nivolumab in a patient with metastatic clear cell renal cell carcinoma and end-stage renal disease on dialysis. <i>Eur Urol</i>. 2016;70(6):1082-1083. doi:10.1016/j.eururo.2016.05.040<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/27311362/pubmed" id="27311362" target="_blank">27311362</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6423951">
<a name="6423951"></a>Centers for Disease Control and Prevention (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. <i>MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/6423951/pubmed" id="6423951" target="_blank">6423951</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33929376">
<a name="33929376"></a>Chalasani NP, Maddur H, Russo MW, Wong RJ, Reddy KR; Practice parameters committee of the American College of Gastroenterology. ACG clinical guideline: diagnosis and management of idiosyncratic drug-induced liver injury. <i>Am J Gastroenterol</i>. 2021;116(5):878-898. doi:10.14309/ajg.0000000000001259<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/33929376/pubmed" id="33929376" target="_blank">33929376</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30298302">
<a name="30298302"></a>Cheun H, Kim M, Lee H, Oh KH, Keam B. Safety and efficacy of immune checkpoint inhibitors for end-stage renal disease patients undergoing dialysis: a retrospective case series and literature review. <i>Invest New Drugs.</i> 2019;37(3):579-583. doi:10.1007/s10637-018-0673-y<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/30298302/pubmed" id="30298302" target="_blank">30298302</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31129384">
<a name="31129384"></a>Chin CK, Hall S, Green C, Van Hazel G, Spagnolo D, Cheah CY. Secondary haemophagocytic lymphohistiocytosis due to checkpoint inhibitor therapy. <i>Eur J Cancer</i>. 2019;115:84-87. doi:10.1016/j.ejca.2019.04.026<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/31129384/pubmed" id="31129384" target="_blank">31129384</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33657295">
<a name="33657295"></a>Choueiri TK, Powles T, Burotto M, et al; CheckMate 9ER Investigators. Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma.<i> N Engl J Med.</i> 2021;384(9):829-841. doi:10.1056/NEJMoa2026982<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/33657295/pubmed" id="33657295" target="_blank">33657295</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31998480">
<a name="31998480"></a>Cordes LM, Davarpanah NN, Reoma LB, et al. Neurotoxicities associated with checkpoint inhibitors: two case reports and a review of the literature. <i>Clin Case Rep</i>. 2019;8(1):24-32. doi:10.1002/ccr3.2534<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/31998480/pubmed" id="31998480" target="_blank">31998480</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27282937">
<a name="27282937"></a>Cortazar FB, Marrone KA, Troxell ML, et al. Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors. <i>Kidney Int</i>. 2016;90(3):638-647. doi:10.1016/j.kint.2016.04.008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/27282937/pubmed" id="27282937" target="_blank">27282937</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30782092">
<a name="30782092"></a>Dasanu CA. Late-onset Stevens-Johnson syndrome due to nivolumab use for hepatocellular carcinoma. <i>J Oncol Pharm Pract</i>. 2019;25(8):2052-2055. doi:10.1177/1078155219830166<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/30782092/pubmed" id="30782092" target="_blank">30782092</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32028838">
<a name="32028838"></a>Dasanu CA, Plaxe SC, Gupta V, Popescu IM, Grover M, Alvarez-Argote J. Severe terminal ileitis induced by single-agent nivolumab administered every four weeks. <i>J Oncol Pharm Pract</i>. 2020;26(6):1516-1519. doi:10.1177/1078155220903367<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/32028838/pubmed" id="32028838" target="_blank">32028838</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36190525">
<a name="36190525"></a>Davis KL, Fox E, Isikwei E, et al. A phase I/II trial of nivolumab plus ipilimumab in children and young adults with relapsed/refractory solid tumors: a Children's Oncology Group Study ADVL1412. <i>Clin Cancer Res</i>. 2022;28(23):5088-5097. doi:10.1158/1078-0432.CCR-22-2164<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/36190525/pubmed" id="36190525" target="_blank">36190525</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29461982">
<a name="29461982"></a>de Almeida DVP, Gomes JR, Haddad FJ, Buzaid AC. Immune-mediated pericarditis with pericardial tamponade during nivolumab therapy. <i>J Immunother</i>. 2018;41(7):329-331. doi:10.1097/CJI.0000000000000217<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/29461982/pubmed" id="29461982" target="_blank">29461982</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30528137">
<a name="30528137"></a>Delanoy N, Michot JM, Comont T, et al. Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study. <i>Lancet Haematol</i>. 2019;6(1):e48-e57. doi:10.1016/S2352-3026(18)30175-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/30528137/pubmed" id="30528137" target="_blank">30528137</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35108470">
<a name="35108470"></a>Doki Y, Ajani JA, Kato K, et al; CheckMate 648 Trial Investigators. Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma. <i>N Engl J Med</i>. 2022;386(5):449-462. doi:10.1056/NEJMoa2111380<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/35108470/pubmed" id="35108470" target="_blank">35108470</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29158217">
<a name="29158217"></a>Escudier M, Cautela J, Malissen N, et al. Clinical features, management, and outcomes of immune checkpoint inhibitor-related cardiotoxicity. <i>Circulation</i>. 2017;136(21):2085-2087. doi:10.1161/CIRCULATIONAHA.117.030571<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/29158217/pubmed" id="29158217" target="_blank">29158217</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31189042">
<a name="31189042"></a>Esfahani K, Buhlaiga N, Thébault P, Lapointe R, Johnson NA, Miller WH Jr. Alemtuzumab for immune-related myocarditis due to PD-1 therapy. <i>N Engl J Med</i>. 2019;380(24):2375-2376. doi:10.1056/NEJMc1903064<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/31189042/pubmed" id="31189042" target="_blank">31189042</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34314320">
<a name="34314320"></a>Fawaz B, Halpern A. Nivolumab-induced granuloma annulare. <i>Cutis</i>. 2021;107(6):E2-E4. doi:10.12788/cutis.0281<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/34314320/pubmed" id="34314320" target="_blank">34314320</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27718784">
<a name="27718784"></a>Ferris RL, Blumenschein G, Fayette J, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. <i>N Engl J Med</i>. 2016;375(19):1856-1867. doi:10.1056/NEJMoa1602252<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/27718784/pubmed" id="27718784" target="_blank">27718784</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35403841">
<a name="35403841"></a>Forde PM, Spicer J, Lu S, et al; CheckMate 816 Investigators. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. <i>N Engl J Med</i>. 2022;386(21):1973-1985. doi:10.1056/NEJMoa2202170<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/35403841/pubmed" id="35403841" target="_blank">35403841</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27367787">
<a name="27367787"></a>Friedman CF, Proverbs-Singh TA, Postow MA. Treatment of the immune-related adverse effects of immune checkpoint inhibitors: a review. <i>JAMA Oncol</i>. 2016;2(10):1346-1353. doi:10.1001/jamaoncol.2016.1051<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/27367787/pubmed" id="27367787" target="_blank">27367787</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29802219">
<a name="29802219"></a>Ganatra S, Neilan TG. Immune checkpoint inhibitor-associated myocarditis. <i>Oncologist</i>. 2018;23(8):879-886. doi:10.1634/theoncologist.2018-0130<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/29802219/pubmed" id="29802219" target="_blank">29802219</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-George.1">
<a name="George.1"></a>George D, Jonasch E. Systemic therapy of advanced clear cell renal carcinoma. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 23, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33017484">
<a name="33017484"></a>Gergi M, Landry KK, Ades S, Barry M, Zakai NA, Herrera DA. Nivolumab-induced thrombotic thrombocytopenic purpura in a patient with anal squamous cell carcinoma: a lesson on hematologic toxicity from immunotherapy. <i>Oncologist</i>. 2020;25(12):1009-1012. doi:10.1002/onco.13553<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/33017484/pubmed" id="33017484" target="_blank">33017484</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25897158">
<a name="25897158"></a>Gettinger SN, Horn L, Gandhi L, et al. Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer. <i>J Clin Oncol</i>. 2015;33(18):2004-2012.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/25897158/pubmed" id="25897158" target="_blank">25897158</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33290581">
<a name="33290581"></a>Gill AJ, Gandhy S, Lancaster E. Nivolumab-associated Lambert-Eaton myasthenic syndrome and cerebellar dysfunction in a patient with a neuroendocrine tumor. <i>Muscle Nerve</i>. 2021;63(3):E18-E21. doi:10.1002/mus.27141<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/33290581/pubmed" id="33290581" target="_blank">33290581</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31311716">
<a name="31311716"></a>Gokozan HN, Friedman JD, Schmaier AH, Downes KA, Farah LA, Reeves HM. Acquired hemophilia A after nivolumab therapy in a patient with metastatic squamous cell carcinoma of the lung successfully managed With rituximab. <i>Clin Lung Cancer</i>. 2019;20(5):e560-e563. doi:10.1016/j.cllc.2019.06.022<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/31311716/pubmed" id="31311716" target="_blank">31311716</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29687056">
<a name="29687056"></a>Griffin LL, Cove-Smith L, Alachkar H, Radford JA, Brooke R, Linton KM. Toxic epidermal necrolysis (TEN) associated with the use of nivolumab (PD-1 inhibitor) for lymphoma. <i>JAAD Case Rep</i>. 2018;4(3):229-231. doi:10.1016/j.jdcr.2017.09.028<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/29687056/pubmed" id="29687056" target="_blank">29687056</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33939491">
<a name="33939491"></a>Griggs JJ, Bohlke K, Balaban EP, et al. Appropriate systemic therapy dosing for obese adult patients with cancer: ASCO guideline update. <i>J Clin Oncol</i>. 2021;39(18):2037-2048. doi:10.1200/JCO.21.00471<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/33939491/pubmed" id="33939491" target="_blank">33939491</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28881921">
<a name="28881921"></a>Haanen JBAG, Carbonnel F, Robert C, et al. Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up [published correction appears in <i>Ann Oncol</i>. 2018;29(Suppl 4):iv264-iv266] [published correction appears in <i>Ann Oncol</i>. 2018;29 Suppl 4:iv264-iv266]. <i>Ann Oncol</i>. 2017;28(suppl_4):iv119-iv142. doi:10.1093/annonc/mdx225<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/28881921/pubmed" id="28881921" target="_blank">28881921</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30012206">
<a name="30012206"></a>Hantel A, Gabster B, Cheng JX, Golomb H, Gajewski TF. Severe hemophagocytic lymphohistiocytosis in a melanoma patient treated with ipilimumab + nivolumab. <i>J Immunother Cancer</i>. 2018;6(1):73.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/30012206/pubmed" id="30012206" target="_blank">30012206</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31647029">
<a name="31647029"></a>Hasegawa T, Ozaki Y, Inoue T, et al. Nivolumab-related severe thrombocytopenia in a patient with relapsed lung adenocarcinoma: a case report and review of the literature. <i>J Med Case Rep</i>. 2019;13(1):316. doi:10.1186/s13256-019-2245-y<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/31647029/pubmed" id="31647029" target="_blank">31647029</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28550712">
<a name="28550712"></a>Hassel JC, Heinzerling L, Aberle J, et al. Combined immune checkpoint blockade (anti-PD-1/anti-CTLA-4): Evaluation and management of adverse drug reactions. <i>Cancer Treat Rev</i>. 2017;57:36-49. doi:10.1016/j.ctrv.2017.05.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/28550712/pubmed" id="28550712" target="_blank">28550712</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Healthy Canadians Recalls &amp; Alerts: Summary Safety Review - Opdivo (nivolumab) and Yervoy (ipilimumab) used alone, or in combination - Health Canada. Health Canada website. <a href="https://hpr-rps.hres.ca/reg-content/summary-safety-review-detail.php?lang=en&amp;linkID=SSR00225" target="_blank">https://hpr-rps.hres.ca/reg-content/summary-safety-review-detail.php?lang=en&amp;linkID=SSR00225</a>. Published: June 24, 2019. Accessed: June 28, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31562796">
<a name="31562796"></a>Hellmann MD, Paz-Ares L, Bernabe Caro R, et al. Nivolumab plus ipilimumab in advanced non-small-cell lung cancer. <i>N Engl J Med</i>. 2019;381(21):2020‐2031. doi:10.1056/NEJMoa1910231<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/31562796/pubmed" id="31562796" target="_blank">31562796</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34114983">
<a name="34114983"></a>Hirasawa Y, Yoshimura K, Matsui H, et al. A case report on severe nivolumab-induced adverse events similar to primary sclerosing cholangitis refractory to immunosuppressive therapy. <i>Medicine (Baltimore)</i>. 2021;100(23):e25774. doi:10.1097/MD.0000000000025774<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/34114983/pubmed" id="34114983" target="_blank">34114983</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35369378">
<a name="35369378"></a>Hirsch JS, Wanchoo R, Ng JH, Khanin Y, Jhaveri KD. Use of immune checkpoint inhibitors in end stage kidney disease patients, single center experience and review of the literature. <i>Kidney360</i>. 2020;1(5):399-402. doi:10.34067/KID.0000422020<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/35369378/pubmed" id="35369378" target="_blank">35369378</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32701815">
<a name="32701815"></a>Hotta M, Naka G, Minamimoto R, Takeda Y, Hojo M. Nivolumab-induced periaortitis demonstrated by FDG PET/CT. <i>Clin Nucl Med</i>. 2020;45(11):910-912. doi:10.1097/RLU.0000000000003215<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/32701815/pubmed" id="32701815" target="_blank">32701815</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29620070">
<a name="29620070"></a>Hussein HM, Dornfeld B, Schneider DJ. Nivolumab-induced posterior reversible encephalopathy syndrome. <i>Neurol Clin Pract</i>. 2017;7(5):455-456. doi:10.1212/CPJ.0000000000000362<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/29620070/pubmed" id="29620070" target="_blank">29620070</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32716741">
<a name="32716741"></a>Hwang JP, Feld JJ, Hammond SP, et al. Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update. <i>J Clin Oncol</i>. 2020;38(31):3698-3715. doi:10.1200/JCO.20.01757<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/32716741/pubmed" id="32716741" target="_blank">32716741</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12534540">
<a name="12534540"></a>Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatitis</i>. 2002;47(5):312-313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/12534540/pubmed" id="12534540" target="_blank">12534540</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35307634">
<a name="35307634"></a>Ismayilov R, Aktepe OH, Sardarova K, Leblebici CB, Erman M. Everolimus and/or nivolumab-associated cytomegalovirus colitis in a patient with metastatic renal cell carcinoma. <i>Eurasian J Med</i>. 2022;54(1):77-79. doi:10.5152/eurasianjmed.2022.20300<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/35307634/pubmed" id="35307634" target="_blank">35307634</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32458394">
<a name="32458394"></a>Iwamoto M, Kato K, Moriyama M, Yamaguchi K, Takahashi S. Remission of ulcerative colitis flare-up induced by nivolumab. <i>Int J Colorectal Dis</i>. 2020;35(9):1791-1795. doi:10.1007/s00384-020-03638-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/32458394/pubmed" id="32458394" target="_blank">32458394</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34102137">
<a name="34102137"></a>Janjigian YY, Shitara K, Moehler M, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. <i>Lancet</i>. 2021;398(10294):27-40. doi:10.1016/S0140-6736(21)00797-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/34102137/pubmed" id="34102137" target="_blank">34102137</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27806233">
<a name="27806233"></a>Johnson DB, Balko JM, Compton ML, et al. Fulminant myocarditis with combination immune checkpoint blockade. <i>N Engl J Med</i>. 2016a;375(18):1749-1755. doi:10.1056/NEJMoa1609214<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/27806233/pubmed" id="27806233" target="_blank">27806233</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28241095">
<a name="28241095"></a>Johnson DB, Sullivan RJ, Menzies AM. Immune checkpoint inhibitors in challenging populations. <i>Cancer</i>. 2017;123(11):1904-1911. doi:10.1002/cncr.30642<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/28241095/pubmed" id="28241095" target="_blank">28241095</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26633184">
<a name="26633184"></a>Johnson DB, Sullivan RJ, Ott PA, et al. Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders. <i>JAMA Oncol</i>. 2016b;2(2):234-240. doi:10.1001/jamaoncol.2015.4368<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/26633184/pubmed" id="26633184" target="_blank">26633184</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31582355">
<a name="31582355"></a>Kato K, Cho BC, Takahashi M, et al. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial. <i>Lancet Oncol</i> 2019;20(11):1506-1517. doi:10.1016/S1470-2045(19)30626-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/31582355/pubmed" id="31582355" target="_blank">31582355</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30017828">
<a name="30017828"></a>Kato R, Hayashi H, Sano K, et al. Nivolumab-induced hemophilia A presenting as gastric ulcer bleeding in a patient with NSCLC. <i>J Thorac Oncol</i>. 2018;13(12):e239-e241. doi:10.1016/j.jtho.2018.06.024<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/30017828/pubmed" id="30017828" target="_blank">30017828</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33789008">
<a name="33789008"></a>Kelly RJ, Ajani JA, Kuzdzal J, et al; CheckMate 577 investigators. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. <i>N Engl J Med.</i> 2021;384(13):1191-1203. doi:10.1056/NEJMoa2032125<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/33789008/pubmed" id="33789008" target="_blank">33789008</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28499515">
<a name="28499515"></a>Khunger M, Rakshit S, Pasupuleti V, et al. Incidence of pneumonitis with use of programmed death 1 and programmed death-ligand 1 inhibitors in non-small cell lung cancer: a systematic review and meta-analysis of trials. <i>Chest</i>. 2017;152(2):271-281. doi:10.1016/j.chest.2017.04.177<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/28499515/pubmed" id="28499515" target="_blank">28499515</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31110718">
<a name="31110718"></a>Kim D. Posterior reversible encephalopathy syndrome induced by nivolumab immunotherapy for non-small-cell lung cancer. <i>Clin Case Rep</i>. 2019;7(5):935-938. doi:10.1002/ccr3.2122<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/31110718/pubmed" id="31110718" target="_blank">31110718</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36108657">
<a name="36108657"></a>Kim S, Wuthrick E, Blakaj D, et al. Combined nivolumab and ipilimumab with or without stereotactic body radiation therapy for advanced Merkel cell carcinoma: a randomised, open label, phase 2 trial. <i>Lancet</i>. 2022;400(10357):1008-1019. doi:10.1016/S0140-6736(22)01659-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/36108657/pubmed" id="36108657" target="_blank">36108657</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37845511">
<a name="37845511"></a>Kirkwood J, Del Vecchio M, Weber J, et al. Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial. <i>Nat Med</i>. 2023. doi:10.1038/s41591-023-02583-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/37845511/pubmed" id="37845511" target="_blank">37845511</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32522380">
<a name="32522380"></a>Klajer E, Garnier L, Goujon M, et al. Targeted and immune therapies among patients with metastatic renal carcinoma undergoing hemodialysis: a systemic review. <i>Semin Oncol</i>. 2020;47(2-3):103-116. doi:10.1053/j.seminoncol.2020.05.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/32522380/pubmed" id="32522380" target="_blank">32522380</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33939308">
<a name="33939308"></a>Koda K, Toyoshima M, Yazawa S, Fukada A, Sugimura H, Suda T. CD8-positive peripheral T cell lymphoma in a patient following long-term nivolumab for advanced lung adenocarcinoma: A case report. <i>Thorac Cancer</i>. 2021;12(11):1765-1769. doi:10.1111/1759-7714.13966<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/33939308/pubmed" id="33939308" target="_blank">33939308</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32888225">
<a name="32888225"></a>Kuba K, Nakahira M, Inoue H, Kogashiwa Y, Ebihara Y, Sugasawa M. Nivolumab-related tracheobronchial chondritis: extremely rare manifestation of an immune-related adverse effect. <i>Head Neck</i>. 2020;42(11):E43-E48. doi:10.1002/hed.26456<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/32888225/pubmed" id="32888225" target="_blank">32888225</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28228726">
<a name="28228726"></a>Kumar V, Chaudhary N, Garg M, Floudas CS, Soni P, Chandra AB. Current diagnosis and management of immune related adverse events (irAEs) induced by immune checkpoint inhibitor therapy [published correction appears in <i>Front Pharmacol</i>. 2017;8:311]. <i>Front Pharmacol</i>. 2017;8:49. doi:10.3389/fphar.2017.00049<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/28228726/pubmed" id="28228726" target="_blank">28228726</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32275077">
<a name="32275077"></a>Kuriyama H, Fukushima S, Nakahara S, et al. Serious disseminated intravascular coagulation associated with combination therapy of nivolumab and ipilimumab in advanced melanoma. <i>J Dermatol</i>. 2020;47(6):e235-e237. doi:10.1111/1346-8138.15336<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/32275077/pubmed" id="32275077" target="_blank">32275077</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26027431">
<a name="26027431"></a>Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. <i>N Engl J Med</i>. 2015;373(1):23-34.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/26027431/pubmed" id="26027431" target="_blank">26027431</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31562797">
<a name="31562797"></a>Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. <i>N Engl J Med</i>. 2019;381(16):1535-1546. doi:10.1056/NEJMoa1910836<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/31562797/pubmed" id="31562797" target="_blank">31562797</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30811280">
<a name="30811280"></a>Lebbé C, Meyer N, Mortier L, et al. Evaluation of two dosing regimens for nivolumab in combination with ipilimumab in patients with advanced melanoma: results from the Phase IIIb/IV CheckMate 511 Trial. <i>J Clin Oncol</i>. 2019;37(11):867-875.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/30811280/pubmed" id="30811280" target="_blank">30811280</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34709662">
<a name="34709662"></a>Li M, Wong D, Vogel AS, et al. Effect of corticosteroid dosing on outcomes in high-grade immune checkpoint inhibitor hepatitis. <i>Hepatology</i>. 2022;75(3):531-540. doi:10.1002/hep.32215<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/34709662/pubmed" id="34709662" target="_blank">34709662</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30018132">
<a name="30018132"></a>Lopez AT, Geskin L. A case of nivolumab-induced bullous pemphigoid: review of dermatologic toxicity associated with programmed cell death protein-1/programmed death ligand-1 inhibitors and recommendations for diagnosis and management. <i>Oncologist</i>. 2018;23(10):1119-1126. doi:10.1634/theoncologist.2018-0128<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/30018132/pubmed" id="30018132" target="_blank">30018132</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30809563">
<a name="30809563"></a>Lu J, Thuraisingam T, Chergui M, Nguyen K. Nivolumab-associated DRESS syndrome: a case report. <i>JAAD Case Rep.</i> 2019;5(3):216-218. doi: 10.1016/j.jdcr.2018.11.017<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/30809563/pubmed" id="30809563" target="_blank">30809563</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10985636">
<a name="10985636"></a>Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43(3):172.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/10985636/pubmed" id="10985636" target="_blank">10985636</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36017568">
<a name="36017568"></a>Lyon AR, López-Fernández T, Couch LS, et al; ESC Scientific Document Group. 2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). <i>Eur Heart J.</i> 2022;43(41):4229-4361. doi:10.1093/eurheartj/ehac244<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/36017568/pubmed" id="36017568" target="_blank">36017568</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29567210">
<a name="29567210"></a>Mahmood SS, Fradley MG, Cohen JV, et al. Myocarditis in patients treated with immune checkpoint inhibitors. <i>J Am Coll Cardiol</i>. 2018;71(16):1755-1764. doi:10.1016/j.jacc.2018.02.037<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/29567210/pubmed" id="29567210" target="_blank">29567210</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35702724">
<a name="35702724"></a>Manjunath J, Mochel M, Nutan F. Nivolumab-induced de novo discoid lupus erythematosus. <i>Case Rep Dermatol</i>. 2022;14(1):88-92. doi:10.1159/000523800<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/35702724/pubmed" id="35702724" target="_blank">35702724</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37164791">
<a name="37164791"></a>Martos-Cabrera L, Lladó I, Fernández-Rico P, Butrón-Bris B, Rodríguez-Jiménez P. Umbilical lichen planus induced by nivolumab. <i>An Bras Dermatol</i>. 2023;98(5):712-714. doi:10.1016/j.abd.2021.09.022<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/37164791/pubmed" id="37164791" target="_blank">37164791</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29159009">
<a name="29159009"></a>Mehta JJ, Maloney E, Srinivasan S, Seitz P, Cannon M. Myasthenia gravis induced by nivolumab: a case report. <i>Cureus</i>. 2017;9(9):e1702. doi:10.7759/cureus.1702<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/29159009/pubmed" id="29159009" target="_blank">29159009</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27687304">
<a name="27687304"></a>Menzies AM, Johnson DB, Ramanujam S, et al. Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. <i>Ann Oncol</i>. 2017;28(2):368-376.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/27687304/pubmed" id="27687304" target="_blank">27687304</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32941716">
<a name="32941716"></a>Messer A, Drozd B, Glitza IC, Lu H, Patel AB. Dermatomyositis associated with nivolumab therapy for melanoma: a case report and review of the literature. <i>Dermatol Online J</i>. 2020;26(8):13030/qt4c21b068. Published 2020 Aug 15.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/32941716/pubmed" id="32941716" target="_blank">32941716</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32191382">
<a name="32191382"></a>Mizuta H, Nakano E, Takahashi A, Koyama T, Namikawa K, Yamazaki N. Hemophagocytic lymphohistiocytosis with advanced malignant melanoma accompanied by ipilimumab and nivolumab: a case report and literature review. <i>Dermatol Ther</i>. 2020;33(3):e13321. doi:10.1111/dth.13321<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/32191382/pubmed" id="32191382" target="_blank">32191382</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29536852">
<a name="29536852"></a>Moslehi JJ, Salem JE, Sosman JA, Lebrun-Vignes B, Johnson DB. Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. <i>Lancet</i>. 2018;391(10124):933. doi:10.1016/S0140-6736(18)30533-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/29536852/pubmed" id="29536852" target="_blank">29536852</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32673417">
<a name="32673417"></a>Motzer RJ, Escudier B, George S, et al. Nivolumab versus everolimus in patients with advanced renal cell carcinoma: updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial. <i>Cancer</i>. 2020;126(18):4156-4167. doi:10.1002/cncr.33033<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/32673417/pubmed" id="32673417" target="_blank">32673417</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26406148">
<a name="26406148"></a>Motzer RJ, Escudier B, McDermott DF, et al; CheckMate 025 Investigators. Nivolumab versus everolimus in advanced renal-cell carcinoma. <i>N Engl J Med</i>. 2015;373(19):1803-1813. doi:10.1056/NEJMoa1510665<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/26406148/pubmed" id="26406148" target="_blank">26406148</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31427204">
<a name="31427204"></a>Motzer RJ, Rini BI, McDermott DF, et al; CheckMate 214 investigators. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. <i>Lancet Oncol</i>. 2019;20(10):1370‐1385. doi:10.1016/S1470-2045(19)30413-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/31427204/pubmed" id="31427204" target="_blank">31427204</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29562145">
<a name="29562145"></a>Motzer RJ, Tannir NM, McDermott DF, et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. <i>N Engl J Med</i>. 2018;378(14):1277-1290. doi:10.1056/NEJMoa1712126<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/29562145/pubmed" id="29562145" target="_blank">29562145</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26371282">
<a name="26371282"></a>Naidoo J, Page DB, Li BT, et al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies [published correction appears in <i>Ann Oncol</i>. 2016;27(7):1362]. <i>Ann Oncol</i>. 2015;26(12):2375-2391. doi:10.1093/annonc/mdv383<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/26371282/pubmed" id="26371282" target="_blank">26371282</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30627102">
<a name="30627102"></a>Nakatani Y, Tanaka N, Enami T, Minami S, Okazaki T, Komuta K. Lambert-Eaton myasthenic syndrome caused by nivolumab in a patient with squamous cell lung cancer. <i>Case Rep Neurol</i>. 2018;10(3):346-352. doi:10.1159/000494078<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/30627102/pubmed" id="30627102" target="_blank">30627102</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33144515">
<a name="33144515"></a>Narayanaswami P, Sanders DB, Wolfe G, et al. International consensus guidance for management of myasthenia gravis: 2020 update. <i>Neurology</i>. 2021;96(3):114-122. doi:10.1212/WNL.0000000000011124<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/33144515/pubmed" id="33144515" target="_blank">33144515</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35811193">
<a name="35811193"></a>Navarro-Triviño FJ, Ruiz-Villaverde R. Photosensitive rash induced by nivolumab. <i>An Bras Dermatol</i>. 2022;97(5):648-650. doi:10.1016/j.abd.2021.07.007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/35811193/pubmed" id="35811193" target="_blank">35811193</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26938948">
<a name="26938948"></a>Nayar N, Briscoe K, Fernandez Penas P. Toxic epidermal necrolysis-like reaction with severe satellite cell necrosis associated with nivolumab in a patient with ipilimumab refractory metastatic melanoma. <i>J Immunother</i>. 2016;39(3):149-152. doi:10.1097/CJI.0000000000000112<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/26938948/pubmed" id="26938948" target="_blank">26938948</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31046841">
<a name="31046841"></a>Noseda R, Bertoli R, Müller L, Ceschi A. Haemophagocytic lymphohistiocytosis in patients treated with immune checkpoint inhibitors: analysis of WHO global database of individual case safety reports. <i>J Immunother Cancer</i>. 2019;7(1):117. doi:10.1186/s40425-019-0598-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/31046841/pubmed" id="31046841" target="_blank">31046841</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18545145">
<a name="18545145"></a>Oble DA, Mino-Kenudson M, Goldsmith J, et al. Alpha-CTLA-4 mAb-associated panenteritis: a histologic and immunohistochemical analysis. <i>Am J Surg Pathol</i>. 2008;32(8):1130-1137. doi:10.1097/PAS.0b013e31817150e3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/18545145/pubmed" id="18545145" target="_blank">18545145</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32517636">
<a name="32517636"></a>Ocampo MM, Lerner J, Dasanu CA. Bluish-gray fingernail discoloration due to the use of nivolumab. <i>J Oncol Pharm Pract</i>. 2021;27(2):457-459. doi:10.1177/1078155220929974<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/32517636/pubmed" id="32517636" target="_blank">32517636</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31043953">
<a name="31043953"></a>Oda H, Ishihara M, Miyahara Y, et al. First case of cytokine release syndrome after nivolumab for gastric cancer. <i>Case Rep Oncol</i>. 2019;12(1):147-156. Published February 8, 2019. doi:10.1159/000496933<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/31043953/pubmed" id="31043953" target="_blank">31043953</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Opdivo.1">
<a name="Opdivo.1"></a>Opdivo (nivolumab) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; October 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Opdivo.2">
<a name="Opdivo.2"></a>Opdivo (nivolumab) [product monograph]. Montreal, Quebec, Canada: Bristol-Myers Squibb Canada Co; December 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31914452">
<a name="31914452"></a>Osmán-García I, Congregado-Ruiz CB, Lendínez-Cano G, Baena-Villamarin C, Conde-Sanchez JM, Medina-López RA. Outcomes and safety of biweekly and monthly nivolumab in patients with metastatic renal cell carcinoma and dialysis: three case reports and literature review. <i>Urol Int</i>. 2020;104(3-4):323-326. doi:10.1159/000504515<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/31914452/pubmed" id="31914452" target="_blank">31914452</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29355075">
<a name="29355075"></a>Overman MJ, Lonardi S, Wong KYM, et al. Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer. <i>J Clin Oncol</i>. 2018;36(8):773-779. doi:10.1200/JCO.2017.76.9901<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/29355075/pubmed" id="29355075" target="_blank">29355075</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28734759">
<a name="28734759"></a>Overman MJ, McDermott R, Leach JL, et al Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. <i>Lancet Oncol</i>. 2017;18(9):1182-1191.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/28734759/pubmed" id="28734759" target="_blank">28734759</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27920704">
<a name="27920704"></a>Palla AR, Kennedy D, Mosharraf H, Doll D. Autoimmune hemolytic anemia as a complication of nivolumab therapy. <i>Case Rep Oncol</i>. 2016;9(3):691-697. doi:10.1159/000452296<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/27920704/pubmed" id="27920704" target="_blank">27920704</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22235228">
<a name="22235228"></a>Palmeira P, Quinello C, Silveira-Lessa AL, Zago CA, Carneiro-Sampaio M. IgG placental transfer in healthy and pathological pregnancies. <i>Clin Dev Immunol</i>. 2012;2012:985646.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/22235228/pubmed" id="22235228" target="_blank">22235228</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30268391">
<a name="30268391"></a>Panariello L, Fattore D, Annunziata MC, Piantedosi F, Gilli M, Fabbrocini G. Bullous pemphigoid and nivolumab: dermatologic management to support and continue oncologic therapy. <i>Eur J Cancer</i>. 2018;103:284-286. doi:10.1016/j.ejca.2018.08.022<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/30268391/pubmed" id="30268391" target="_blank">30268391</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Paz-Ares L, Ciuleanu TE, Cobo M, et al. First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. <i>Lancet Oncol</i>. 2021;22(2):198-211. doi:10.1016/S1470-2045(20)30641-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/33476593/pubmed" id="33476593" target="_blank">33476593</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19626656">
<a name="19626656"></a>Pentsuk N, van der Laan JW. An interspecies comparison of placental antibody transfer: new insights into developmental toxicity testing of monoclonal antibodies. <i>Birth Defects Res B Dev Reprod Toxicol</i>. 2009;86(4):328-344.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/19626656/pubmed" id="19626656" target="_blank">19626656</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35124183">
<a name="35124183"></a>Peters S, Scherpereel A, Corenelissen R, et al. First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743. <i>Ann Oncol.</i> 2022;33(5):488-499. doi:10.1016/j.annonc.2022.01.074<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/35124183/pubmed" id="35124183" target="_blank">35124183</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25891304">
<a name="25891304"></a>Postow MA, Chesney J, Pavlick AC, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. <i>N Engl J Med</i>. 2015;372(21):2006-2017.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/25891304/pubmed" id="25891304" target="_blank">25891304</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29320654">
<a name="29320654"></a>Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. <i>N Engl J Med</i>. 2018;378(2):158-168. doi:10.1056/NEJMra1703481<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/29320654/pubmed" id="29320654" target="_blank">29320654</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35728020">
<a name="35728020"></a>Rathmell WK, Rumble RB, Van Veldhuizen PJ, et al. Management of metastatic clear cell renal cell carcinoma: ASCO guideline. <i>J Clin Oncol</i>. 2022;40(25):2957-2995. doi:10.1200/JCO.22.00868<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/35728020/pubmed" id="35728020" target="_blank">35728020</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29951303">
<a name="29951303"></a>Remon J, Mezquita L, Corral J, Vilariño N, Reguart N. Immune-related adverse events with immune checkpoint inhibitors in thoracic malignancies: focusing on non-small cell lung cancer patients. <i>J Thorac Dis</i>. 2018;10(suppl 13):S1516-S1533. doi:10.21037/jtd.2017.12.52<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/29951303/pubmed" id="29951303" target="_blank">29951303</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25704439">
<a name="25704439"></a>Rizvi NA, Mazières J, Planchard D, et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. <i>Lancet Oncol</i>. 2015;16(3):257-265.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/25704439/pubmed" id="25704439" target="_blank">25704439</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-253995524">
<a name="253995524"></a>Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. <i>N Engl J Med</i>. 2015;372(4):320-330.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/253995524/pubmed" id="253995524" target="_blank">253995524</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25891173">
<a name="25891173"></a>Robert C, Schachter J, Long GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma. <i>N Engl J Med</i>. 2015;372(26):2521-2532. doi:10.1056/NEJMoa1503093<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/25891173/pubmed" id="25891173" target="_blank">25891173</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29045532">
<a name="29045532"></a>Salati M, Pifferi M, Baldessari C, et al. Stevens-Johnson syndrome during nivolumab treatment of NSCLC. <i>Ann Oncol</i>. 2018;29(1):283-284. doi:10.1093/annonc/mdx640<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/29045532/pubmed" id="29045532" target="_blank">29045532</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32448839">
<a name="32448839"></a>Samejima Y, Iuchi A, Kanai T, et al. Development of severe heart failure in a patient with squamous non-small-cell lung cancer during vivolumab treatment. <i>Intern Med</i>. 2020;59(16):2003-2008. doi:10.2169/internalmedicine.4550-20<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/32448839/pubmed" id="32448839" target="_blank">32448839</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34148954">
<a name="34148954"></a>Sato I. Lip ulcer induced by nivolumab: a case report. <i>Intern Med</i>. 2021;60(23):3847-3848. doi:10.2169/internalmedicine.7151-21<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/34148954/pubmed" id="34148954" target="_blank">34148954</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34092733">
<a name="34092733"></a>Sawada R, Matsui Y, Uchino J, et al. Late-onset pleural and pericardial effusion as immune-related adverse events after 94 cycles of nivolumab. <i>Intern Med</i>. 2021;60(22):3585-3588. doi:10.2169/internalmedicine.7219-21<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/34092733/pubmed" id="34092733" target="_blank">34092733</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29472154">
<a name="29472154"></a>Satzger I, Ivanyi P, Länger F, et al. Treatment-related hemophagocytic lymphohistiocytosis secondary to checkpoint inhibition with nivolumab plus ipilimumab. <i>Eur J Cancer</i>. 2018;93:150-153. doi:10.1016/j.ejca.2018.01.063<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/29472154/pubmed" id="29472154" target="_blank">29472154</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34724392">
<a name="34724392"></a>Schneider BJ, Naidoo J, Santomasso BD, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO Guideline Update [published correction appears in J Clin Oncol. 2022 Jan 20;40(3):315]. <i>J Clin Oncol</i>. 2021;39(36):4073-4126. doi:10.1200/JCO.21.01440<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/34724392/pubmed" id="34724392" target="_blank">34724392</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29669775">
<a name="29669775"></a>Shaikh H, Daboul N, Albrethsen M, Fazal S. A case of autoimmune haemolytic anaemia after 39 cycles of nivolumab. <i>BMJ Case Rep</i>. 2018;2018:bcr2018224608. doi:10.1136/bcr-2018-224608<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/29669775/pubmed" id="29669775" target="_blank">29669775</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28131785">
<a name="28131785"></a>Sharma P, Retz M, Siefker-Radtke A, et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. <i>Lancet Oncol</i>. 2017;18(3):312-322.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/28131785/pubmed" id="28131785" target="_blank">28131785</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33725559">
<a name="33725559"></a>Shaw LK, Wiele AJ, Sircar K, Wood CG, Msaouel P. Safe and effective use of nivolumab plus ipilimumab in a patient with metastatic clear-cell renal cell carcinoma with sarcomatoid dedifferentiation and end stage renal disease on hemodialysis. <i>Cancer Treat Res Commun</i>. 2021;27:100349. doi:10.1016/j.ctarc.2021.100349<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/33725559/pubmed" id="33725559" target="_blank">33725559</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7746084">
<a name="7746084"></a>Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet</i>. 1995;345(8960):1312-1313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/7746084/pubmed" id="7746084" target="_blank">7746084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31290394">
<a name="31290394"></a>Shibata A, Yoshikawa T, Makita S, Nakagawa S, Ueda Y, Akiyama M. A case of recurrent Stevens-Johnson syndrome caused by nivolumab therapy [published online ahead of print, 2019 Jul 10]. <i>Eur J Dermatol</i>. 2019;10.1684/ejd.2019.3550. doi:10.1684/ejd.2019.3550<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/31290394/pubmed" id="31290394" target="_blank">31290394</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28426103">
<a name="28426103"></a>Spain L, Walls G, Julve M, et al. Neurotoxicity from immune-checkpoint inhibition in the treatment of melanoma: a single centre experience and review of the literature. <i>Ann Oncol</i>. 2017;28(2):377-385. doi:10.1093/annonc/mdw558<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/28426103/pubmed" id="28426103" target="_blank">28426103</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32301024">
<a name="32301024"></a>Srivastava A, Al-Zubidi N, Appelbaum E, et al. Immune-related oral, otologic, and ocular adverse events. <i>Adv Exp Med Biol</i>. 2020;1244:295-307. doi:10.1007/978-3-030-41008-7_17<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/32301024/pubmed" id="32301024" target="_blank">32301024</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33650723">
<a name="33650723"></a>Suenaga A, Ito T, Eto A, Furue M. Acral ischemia induced by nivolumab: A case report. <i>J Dermatol</i>. 2021;48(5):e223-e224. doi:10.1111/1346-8138.15830<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/33650723/pubmed" id="33650723" target="_blank">33650723</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32594423">
<a name="32594423"></a>Sugimoto S, Terashima T, Yamashita T, et al. Tumor lysis syndrome in a patient with metastatic melanoma treated with nivolumab. <i>Clin J Gastroenterol</i>. 2020;13(5):935-939. doi:10.1007/s12328-020-01164-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/32594423/pubmed" id="32594423" target="_blank">32594423</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29603856">
<a name="29603856"></a>Suzman DL, Pelosof L, Rosenberg A, Avigan MI. Hepatotoxicity of immune checkpoint inhibitors: an evolving picture of risk associated with a vital class of immunotherapy agents. <i>Liver Int</i>. 2018;38(6):976-987. doi:10.1111/liv.13746<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/29603856/pubmed" id="29603856" target="_blank">29603856</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28734029">
<a name="28734029"></a>Tabei T, Natsume I, Kobayashi K. Successful treatment of metastatic clear cell carcinoma with nivolumab in a patient receiving dialysis treatment. <i>Int J Urol</i>. 2017;24(9):708-710. doi:10.1111/iju.13420<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/28734029/pubmed" id="28734029" target="_blank">28734029</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31700625">
<a name="31700625"></a>Takamatsu D, Furubayashi N, Negishi T, et al. Relapse of aseptic meningitis induced by ipilimumab and nivolumab therapy for metastatic renal cell carcinoma: a case report. <i>Mol Clin Oncol</i>. 2019;11(6):590-594. doi:10.3892/mco.2019.1929<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/31700625/pubmed" id="31700625" target="_blank">31700625</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32703012">
<a name="32703012"></a>Tampio AJF, Dhanireddy S, Sivapiragasam A, Nicholas BD. Bilateral sensorineural hearing loss associated with nivolumab therapy for stage IV malignant melanoma. <i>Ear Nose Throat J</i>. 2021;100(3_suppl):286S-291S. doi:10.1177/0145561320940847<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/32703012/pubmed" id="32703012" target="_blank">32703012</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30347480">
<a name="30347480"></a>Tanios GE, Doley PB, Munker R. Autoimmune hemolytic anemia associated with the use of immune checkpoint inhibitors for cancer: 68 cases from the Food and Drug Administration database and review. <i>Eur J Haematol</i>. 2019;102(2):157-162. doi:10.1111/ejh.13187<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/30347480/pubmed" id="30347480" target="_blank">30347480</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30134131">
<a name="30134131"></a>Tawbi HA, Forsyth PA, Algazi A, et al. Combined nivolumab and ipilimumab in melanoma metastatic to the brain. <i>N Engl J Med</i>. 2018;379(8):722-730.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/30134131/pubmed" id="30134131" target="_blank">30134131</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34774225">
<a name="34774225"></a>Tawbi HA, Forsyth PA, Hodi FS, et al. Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study. <i>Lancet Oncol</i>. 2021;22(12):1692-1704. doi:10.1016/S1470-2045(21)00545-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/34774225/pubmed" id="34774225" target="_blank">34774225</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30865922">
<a name="30865922"></a>Thompson JA, Schneider BJ, Brahmer J, et al. Management of immunotherapy-related toxicities, version 1.2019. <i>J Natl Compr Canc Netw</i>. 2019;17(3):255-289. doi:10.6004/jnccn.2019.0013<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/30865922/pubmed" id="30865922" target="_blank">30865922</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28651328">
<a name="28651328"></a>Tomita Y, Sueta D, Kakiuchi Y, et al. Acute coronary syndrome as a possible immune-related adverse event in a lung cancer patient achieving a complete response to anti-PD-1 immune checkpoint antibody. <i>Ann Oncol</i>. 2017;28(11):2893-2895. doi:10.1093/annonc/mdx326<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/28651328/pubmed" id="28651328" target="_blank">28651328</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24590637">
<a name="24590637"></a>Topalian SL, Sznol M, McDermott DF, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. <i>J Clin Oncol</i>. 2014;32(10):1020-1030.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/24590637/pubmed" id="24590637" target="_blank">24590637</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31823117">
<a name="31823117"></a>Tso DK, Avery LL, Lev MH, Kamalian S. Nivolumab-induced small bowel obstruction and perforation: a rare but life-threatening side effect of immunotherapy. <i>Emerg Radiol</i>. 2020;27(1):107-110. doi:10.1007/s10140-019-01731-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/31823117/pubmed" id="31823117" target="_blank">31823117</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31309615">
<a name="31309615"></a>Tsung I, Dolan R, Lao CD, et al. Liver injury is most commonly due to hepatic metastases rather than drug hepatotoxicity during pembrolizumab immunotherapy. <i>Aliment Pharmacol Ther</i>. 2019;50(7):800-808. doi:10.1111/apt.15413<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/31309615/pubmed" id="31309615" target="_blank">31309615</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32270507">
<a name="32270507"></a>Uehara J, Yoshino K, Sugiyama E, et al. Immune-related pancytopenia caused by nivolumab and ipilimumab combination therapy for unresectable melanoma of unknown primary. <i>J Dermatol</i>. 2020;47(6):e237-e239. doi:10.1111/1346-8138.15341<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/32270507/pubmed" id="32270507" target="_blank">32270507</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26629425">
<a name="26629425"></a>Villadolid J, Amin A. Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities. <i>Transl Lung Cancer Res</i>. 2015;4(5):560-575. doi:10.3978/j.issn.2218-6751.2015.06.06<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/26629425/pubmed" id="26629425" target="_blank">26629425</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31375351">
<a name="31375351"></a>Vitale MG, Baldessari C, Milella M, et al. Immunotherapy in dialysis-dependent cancer patients: our experience in patients with metastatic renal cell carcinoma and a review of the literature. <i>Clin Genitourin Cancer</i>. 2019;17(5):e903-e908. doi:10.1016/j.clgc.2019.06.009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/31375351/pubmed" id="31375351" target="_blank">31375351</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34524642">
<a name="34524642"></a>Wakabayashi K, Yamamoto S, Hara S, et al. Nivolumab-induced membranous nephropathy in a patient with stage IV lung adenocarcinoma. <i>CEN Case Rep</i>. 2022;11(2):171-176. doi:10.1007/s13730-021-00645-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/34524642/pubmed" id="34524642" target="_blank">34524642</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28891423">
<a name="28891423"></a>Weber J, Mandala M, Del Vecchio M, et al; CheckMate 238 Collaborators. Adjuvant nivolumab versus ipilimumab in resected Stage III or IV melanoma. <i>N Engl J Med</i>. 2017;377(19):1824-1835. doi:10.1056/NEJMoa1709030<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/28891423/pubmed" id="28891423" target="_blank">28891423</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25795410">
<a name="25795410"></a>Weber JS, D'Angelo SP, Minor D, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. <i>Lancet Oncol</i>. 2015;16(4):375-384.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/25795410/pubmed" id="25795410" target="_blank">25795410</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22614989">
<a name="22614989"></a>Weber JS, Kähler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. <i>J Clin Oncol</i>. 2012;30(21):2691-2697. doi:10.1200/JCO.2012.41.6750<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/22614989/pubmed" id="22614989" target="_blank">22614989</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25918278">
<a name="25918278"></a>Weber JS, Yang JC, Atkins MB, Disis ML. Toxicities of immunotherapy for the practitioner. <i>J Clin Oncol</i>. 2015;33(18):2092-2099. doi:10.1200/JCO.2014.60.0379<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/25918278/pubmed" id="25918278" target="_blank">25918278</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28889792">
<a name="28889792"></a>Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. <i>N Engl J Med</i>. 2017;377(14):1345-1356. doi:10.1056/NEJMoa1709684<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/28889792/pubmed" id="28889792" target="_blank">28889792</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32847555">
<a name="32847555"></a>Yamada H, Okajima F, Onda T, Fujimori S, Emoto N, Sugihara H. New-onset graves' disease after the initiation of nivolumab therapy for gastric cancer: a case report. <i>BMC Endocr Disord</i>. 2020;20(1):132. doi:10.1186/s12902-020-00613-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/32847555/pubmed" id="32847555" target="_blank">32847555</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36911644">
<a name="36911644"></a>Yang HH, Chang CW, Chen TD. Nivolumab-induced acute tubular injury: a case report. <i>Clin Case Rep</i>. 2023;11(3):e6991. doi:10.1002/ccr3.6991<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/36911644/pubmed" id="36911644" target="_blank">36911644</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33001135">
<a name="33001135"></a>Yau T, Kang YK, Kim TY, et al. Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib: the CheckMate 040 randomized clinical trial. <i>JAMA Oncol</i>. 2020;6(11):e204564. doi:10.1001/jamaoncol.2020.4564<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/33001135/pubmed" id="33001135" target="_blank">33001135</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27451390">
<a name="27451390"></a>Younes A, Santoro A, Shipp M, et al. Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicenter, multicohort, single-arm phase 2 trial. <i>Lancet Oncol</i>. 2016;17(9):1283-1294.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/27451390/pubmed" id="27451390" target="_blank">27451390</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35989738">
<a name="35989738"></a>Zahoor F, Ahmed N, Afzal G. Onychopathy induced by nivolumab: a targeted immunotherapy. <i>Cureus</i>. 2022;14(7):e26950. doi:10.7759/cureus.26950<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/35989738/pubmed" id="35989738" target="_blank">35989738</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27084345">
<a name="27084345"></a>Zimmer L, Goldinger SM, Hofmann L, et al. Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy. <i>Eur J Cancer</i>. 2016;60:210-225. doi:10.1016/j.ejca.2016.02.024<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/27084345/pubmed" id="27084345" target="_blank">27084345</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30489484">
<a name="30489484"></a>Zitouni NB, Arnault JP, Dadban A, Attencourt C, Lok CC, Chaby G. Subacute cutaneous lupus erythematosus induced by nivolumab: two case reports and a literature review. <i>Melanoma Res</i>. 2019;29(2):212-215.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/30489484/pubmed" id="30489484" target="_blank">30489484</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 115765 Version 188.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
